Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Skin Neoplasms: Tumors or cancer of the SKIN.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.DNA, Neoplasm: DNA present in neoplastic tissue.Lung Neoplasms: Tumors or cancer of the LUNG.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Neoplasms, Connective and Soft Tissue: Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.Neoplasms, Plasma Cell: Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Liver Neoplasms: Tumors or cancer of the LIVER.Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Endocrine Gland Neoplasms: Tumors or cancer of the ENDOCRINE GLANDS.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Neoplasms, Vascular Tissue: Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.Eye Neoplasms: Tumors or cancer of the EYE.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Nose Neoplasms: Tumors or cancer of the NOSE.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Neoplasms, Radiation-Induced: Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasms, Muscle Tissue: Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Adenoma: A benign epithelial tumor with a glandular organization.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Uterine Neoplasms: Tumors or cancer of the UTERUS.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Neoplasms, Adnexal and Skin Appendage: Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Vascular Neoplasms: Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.Sweat Gland NeoplasmsLymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Palatal Neoplasms: Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.Neoplasms, Complex and Mixed: Neoplasms composed of more than one type of neoplastic tissue.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Mandibular Neoplasms: Tumors or cancer of the MANDIBLE.Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Splenic Neoplasms: Tumors or cancer of the SPLEEN.Heart Neoplasms: Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Colonic Neoplasms: Tumors or cancer of the COLON.Maxillary Neoplasms: Cancer or tumors of the MAXILLA or upper jaw.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Anal Gland Neoplasms: Tumors or cancer of the anal gland.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.Neoplasms, Adipose Tissue: Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Mouth Neoplasms: Tumors or cancer of the MOUTH.Mediastinal Neoplasms: Tumors or cancer of the MEDIASTINUM.Tongue Neoplasms: Tumors or cancer of the TONGUE.Ileal Neoplasms: Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).Stomach Neoplasms: Tumors or cancer of the STOMACH.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Carcinoma, Acinar Cell: A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)Spinal Cord Neoplasms: Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.Vaginal Neoplasms: Tumors or cancer of the VAGINA.Adenoma, Oxyphilic: A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Nervous System Neoplasms: Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.Janus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Myelodysplastic-Myeloproliferative Diseases: Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Peripheral Nervous System Neoplasms: Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)Cerebral Ventricle Neoplasms: Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.Paranasal Sinus Neoplasms: Tumors or cancer of the PARANASAL SINUSES.Pleural Neoplasms: Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.Breast Neoplasms: Tumors or cancer of the human BREAST.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Orbital Neoplasms: Neoplasms of the bony orbit and contents except the eyeball.Abdominal NeoplasmsCerebellar Neoplasms: Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)Lipoma: A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.Facial NeoplasmsRetrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Neoplasms by Site: A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Histiocytic Disorders, Malignant: Distinctive neoplastic disorders of histiocytes. Included are malignant neoplasms of MACROPHAGES and DENDRITIC CELLS.Urogenital Neoplasms: Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.Spinal NeoplasmsSkull Neoplasms: Neoplasms of the bony part of the skull.Vulvar Neoplasms: Tumors or cancer of the VULVA.Neoplasms, Neuroepithelial: Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)Ear Neoplasms: Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).Lip Neoplasms: Tumors or cancer of the LIP.Fibroma: A benign tumor of fibrous or fully developed connective tissue.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Adrenal Gland Neoplasms: Tumors or cancer of the ADRENAL GLANDS.Pelvic Neoplasms: Tumors or cancer of the pelvic region.Gingival NeoplasmsGallbladder Neoplasms: Tumors or cancer of the gallbladder.Neoplasm Seeding: The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.Neoplasms, Fibroepithelial: Neoplasms composed of fibrous and epithelial tissue. The concept does not refer to neoplasms located in fibrous tissue or epithelium.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Respiratory Tract NeoplasmsNeoplasms, Connective Tissue: Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Primary Myelofibrosis: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.Thrombocythemia, Essential: A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.RNA, Neoplasm: RNA present in neoplastic tissue.Trophoblastic Neoplasms: Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691)Hemangioma: A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Rodent Diseases: Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).Thoracic NeoplasmsCecal Neoplasms: Tumors or cancer of the CECUM.Leukemia, B-Cell: A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.Hemangioendothelioma: A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)Adenoma, Pleomorphic: A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)Digestive System Neoplasms: Tumors or cancer of the DIGESTIVE SYSTEM.Tracheal NeoplasmsAdenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Jejunal Neoplasms: Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Neurilemmoma: A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)Biopsy, Fine-Needle: Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.Central Nervous System Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Carcinosarcoma: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)Cyst Fluid: Liquid material found in epithelial-lined closed cavities or sacs.Carcinogens: Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.Adenoma, Liver Cell: A benign epithelial tumor of the LIVER.Pituitary Neoplasms: Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.Histiocytic Sarcoma: Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.Keratoacanthoma: A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption.Pseudomyxoma Peritonei: A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)Carcinogenicity Tests: Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Genital Neoplasms, Male: Tumor or cancer of the MALE GENITALIA.Infratentorial Neoplasms: Intracranial tumors originating in the region of the brain inferior to the tentorium cerebelli, which contains the cerebellum, fourth ventricle, cerebellopontine angle, brain stem, and related structures. Primary tumors of this region are more frequent in children, and may present with ATAXIA; CRANIAL NERVE DISEASES; vomiting; HEADACHE; HYDROCEPHALUS; or other signs of neurologic dysfunction. Relatively frequent histologic subtypes include TERATOMA; MEDULLOBLASTOMA; GLIOBLASTOMA; ASTROCYTOMA; EPENDYMOMA; CRANIOPHARYNGIOMA; and choroid plexus papilloma (PAPILLOMA, CHOROID PLEXUS).Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.Iris Neoplasms: Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Urethral Neoplasms: Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Granulosa Cell Tumor: A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.Mammary Neoplasms, Animal: Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).Perivascular Epithelioid Cell Neoplasms: A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).Rats, Inbred F344Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Biopsy, Needle: Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Mesenchymoma: A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)Rectal Neoplasms: Tumors or cancer of the RECTUM.Lymphoma, T-Cell: A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Cat Diseases: Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).Submandibular Gland NeoplasmsPapilloma: A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Myoepithelioma: A usually benign tumor made up predominantly of myoepithelial cells.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Eyelid Neoplasms: Tumors of cancer of the EYELIDS.Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.Hypothalamic Neoplasms: Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051)Oligodendroglioma: A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)Histiocytoma, Benign Fibrous: A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)Meningioma: A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Carcinoid Tumor: A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Maxillary Sinus Neoplasms: Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms.

*  Rectosigmoid neoplasm | Disease | News & Events | Office of Rare Diseases Research (ORDR-NCATS)
... Office of Rare Diseases Research ORDR-NCATS. ORDR Office of Rare Diseases Research. Genetic and Rare Diseases Information Center GARD. Search for Genetic Rare Diseases Search. Rare Diseases Resources. Quick Links Rare Diseases Clinical Research Network RDCRN. Search for Conferences on Rare Diseases Search. About the Office of Rare Diseases Research ORDR. ORDR Co-Sponsored Conferences Rare Tumors Initiative Symposium Strategies to Develop Therapies for Rare Tumors: Small Numbers, but Big Opportunities, Wednesday, June 17, 2015 Location: NIH Natcher Conference Center, Bethesda, MD Description: The goals of this symposium are to increase communication and build networks between researchers working in rare tumors across NIH, and to get input from patient groups, industry, and the FDA on how to overcome the biggest hurdles in the development of therapies for rare tumors. Overcoming Barriers to International Clinical Trials for Rare Cancers, Friday, December 10, 2010 Location: Bethesda, Maryland Description: Th...
https://rarediseases.info.nih.gov/gard/7534/rectosigmoid-neoplasm/resources/4
*  2011 ICD-9-CM Diagnosis Code 161.1 : Malignant neoplasm of supraglottis
Diagnosis Codes > Neoplasms 140-239 > Malignant Neoplasm Of ... 2011 ICD-9-CM Diagnosis Code 161.1 : Malignant neoplasm of supraglottis. Home > 2011 ICD-9-CM Diagnosis Codes > Neoplasms 140-239 > Malignant Neoplasm Of Respiratory And Intrathoracic Organs 160-165 > Malignant neoplasm of larynx 161-. 2011 ICD-9-CM Diagnosis Code 161.1. Malignant neoplasm of supraglottis. Short description: Malig neo supraglottis. ICD-9-CM 161.1 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 161.1 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code or codes. You are viewing the 2011 version of ICD-9-CM 161.1. More recent version s of ICD-9-CM 161.1 : 2012 2013 2014 2015. Convert to ICD-10-CM : 161.1 converts directly to: 2015/16 ICD-10-CM C32.1 Malignant neoplasm of supraglottis. Disease Synonyms Cancer of the epiglottis Cancer of the supraglot...
http://icd9data.com/2011/Volume1/140-239/160-165/161/161.1.htm
*  Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®): Treatment - Patient Informatio
Plasma Cell Neoplasms Including Multiple Myeloma Treatment ... About Plasma Cell Neoplasms. Stages of Plasma Cell Neoplasms. ... Plasma Cell Neoplasms. Treatment Option Overview. Treatment ... Plasma Cell Neoplasms Including Multiple Myeloma Treatment PDQ® : Treatment - Patient Information. Plasma Cell Neoplasms Including Multiple Myeloma Treatment PDQ® : Treatment - Patient Information. In isolated plasmacytoma of bone, one plasma cell tumor is found in the bone, less than 10% of the bone marrow is made up of plasma cells, and there are no other signs of cancer. Plasmacytoma of the bone often becomes multiple myeloma. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with isolated plasmacytoma of bone. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with extramedullary plasmacytoma. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with refractory multiple myeloma. To Learn More A...
http://peacehealth.org/medical-topics/content/nci/ncicdr0000258195.html
*  TY - JOUR T1 - CL...
the radiotherapy of neoplasms, is by Windeyer and Colwell. In his own ......
http://jama.jamanetwork.com/downloadCitation.aspx?format=ris&articleid=289211
*  Emigration theory - Biology-Online Dictionary
theory. That neoplasms originate from various cell rests , i.e ... emigration theory biology online dictionary join for free login welcome to biology online login remember me answers to all your biology questions home blog forum dictionary articles tutorials books directory share search quick links a b c d e f g h i j k l m n o p q r s t u v w x y z other view view source history emigration theory emigration theory cohnheims theory that neoplasms originate from various cell rests i e embryonal cells thought to persist in various sites after the development of the foetal organs and tissues synonym emigration theory retrieved from http www biology online org bodict index php title emigration theory oldid first previous emigration next eminence last please contribute to this project if you ha...
http://biology-online.org/dictionary/Emigration_theory
*  Central California Chapter | Events & Information | LLS
Myeloproliferative Neoplasms. Childhood Blood Cancer. Managing ... Central California Chapter. LLS. Why Give to LLS. Chapters. All Chapters. Contact LLS. Continuing Education. Continuing Education Programs. Continuing Medical Education Programs. Support Resources. Contact an Information Specialist. Peer-to-Peer Support. Education Resources. Team LLS. Team In Training. Light The Night Walk. Man Woman of the Year. Here you can find ways to participate in local events supporting our research, patient support & information programs. Here you can find ways to participate in local events supporting our research, patient support & information programs. The Leukemia Lymphoma Society's Team In Training funds treatments that are saving the lives of patients today. There are many different ways you can participate in the South Central Texas Chapter and make a difference in the lives of those touched by blood cancer. The Leukemia Lymphoma Society LLS sponsors free community-based education programs for patients, t...
http://lls.org/central-california
*  2010 ICD-9-CM Diagnosis Code 209.50 : Benign carcinoid tumor of the large intestine, unspe
Diagnosis Codes > Neoplasms 140-239 > Neuroendocrine Tumors 209-209 ... 2010 ICD-9-CM Diagnosis Code 209.50 : Benign carcinoid tumor of the large intestine, unspecified portion. Home > 2010 ICD-9-CM Diagnosis Codes > Neoplasms 140-239 > Neuroendocrine Tumors 209-209 > Neuroendocrine tumors 209-. 2010 ICD-9-CM Diagnosis Code 209.50. Benign carcinoid tumor of the large intestine, unspecified portion. ICD-9-CM 209.50 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 209.50 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code or codes. More recent version s of ICD-9-CM 209.50 : 2011 2012 2013 2014 2015. Convert to ICD-10-CM : 209.50 converts directly to: 2015/16 ICD-10-CM D3A.029 Benign carcinoid tumor of the large intestine, unspecified portion. Disease Synonyms Benign carcinoid of large intestine Benign carcinoid tumor large intest...
http://icd9data.com/2010/Volume1/140-239/209-209/209/209.50.htm
*  Texas Department of State Health Services, Center for Health Statistics 2005 Annual Report, Mortalit
of death, malignant neoplasms cancer , accounted for 21.9 percent. ... heart, malignant neoplasms, and cerebrovascular diseases, ... in 2005. Malignant neoplasms were responsible for 12.1 percent of ... The leading cause of death, diseases of the heart, accounted for 25.7 percent of those deaths, while the second most common cause of death, malignant neoplasms cancer , accounted for 21.9 percent. The infant mortality rate increased to 6.5 infant deaths per 1,000 live births. The top three leading causes of death, diseases of the heart, malignant neoplasms, and cerebrovascular diseases, accounted for 53.6 percent of all Texas resident deaths in 2005. Malignant neoplasms were responsible for 12.1 percent of all deaths to this age group and diseases of the heart claimed the lives of another 9.5 percent. Although males represented half 50.0 percent of the Texas population in 2005, they accounted for 60.6 percent of all deaths to persons 1 through 74 years of age. Infant Mortality There were 2,515 infant deat...
http://dshs.state.tx.us/chs/vstat/vs05/nmortal.shtm
*  E-Mail This Page - National Cancer Institute
Myeloproliferative Neoplasms Treatment PDQ®. Send this link to e-...
http://cancer.gov/Common/PopUps/Email.aspx?title=Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)&docurl=/cancertopics/pdq/treatment/mds-mpd/HealthProfessional/page4&language=en&a=P-2142544558&b=2801v4
*  Loss of heterozygosity of selected tumor suppressor genes in human testicular germ cell tumors - Rep
heterogenous neoplasms with a variable malignant potential. ... Loss of heterozygosity of selected tumor suppressor genes in human testicular germ cell tumors - Repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu. Repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu. Loss of heterozygosity of selected tumor suppressor genes in human testicular germ cell tumors. Vladušić, Tomislav and Hrašćan, Reno and Vrhovac, Ivana and Krušlin, Božo and Gamulin, Marija and Grgić, Mislav and Pećina-Šlaus, Nives and Franekić Čolić, Jasna 2010 Loss of heterozygosity of selected tumor suppressor genes in human testicular germ cell tumors. Official URL: http://www.elsevier.com/locate/issn/03440338 English abstract Human testicular germ cell tumors TGCTs are histologically heterogenous neoplasms with a variable malignant potential. Two main groups of germ cell tumors occur in men: seminomas and nonseminomas. In the present study, a set of four tumor suppressor genes was investigated in testicular cancers. CDH1, APC, p53, ...
http://medlib.mef.hr/708/
*  Pancreatic Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI]-Stage III Pan
Pancreatic Cancer Treatment PDQ® : Treatment - Health Professional Information -Stage III Pancreatic Cancer Treatment. Cancer. Pancreatic Cancer Treatment PDQ® : Treatment - Health Professional Information - Stage III Pancreatic Cancer Treatment Pancreatic Cancer Treatment PDQ® : Treatment - Health Professional Information Guide General Information About Pancreatic Cancer. Randomized Studies in Stage III Pancreatic Cancer: Median Survival continued... Before the use of gemcitabine for patients with locally advanced or metastatic pancreatic cancer, investigators from the GITSG randomly assigned 106 patients with locally advanced pancreatic adenocarcinoma to receive external-beam radiation therapy EBRT 60 Gy alone or concurrent EBRT either 40 Gy or 60 Gy plus bolus 5-FU. ECOG: The results of the FFCD-SFRO study stand in contrast to the results of a study from ECOG in which investigators randomly assigned 74 patients to either gemcitabine alone or gemcitabine with radiation followed by gemcitabine. Groupe Coopér...
http://webmd.com/cancer/pancreatic-cancer/tc/pancreatic-cancer-treatment-pdq-treatment---health-professional-information-nci-stage-iii-pancreatic-cancer-treatment?page=2
*  Discovery offers potential new pancreatic cancer treatment | EurekAlert! Science News
Discovery offers potential new pancreatic cancer treatment. EurekAlert. Science News. News. Breaking News. Science Business News. EurekAlert!中文版. Cancer Research. Breaking News. Science Business News. EurekAlert. Featured Meeting American Chemical Society 250th National Meeting Exposition August 16-20, 2015 Boston, MA More Information. About EurekAlert. Help / FAQ. Public Release: 2-Nov-2009 Discovery offers potential new pancreatic cancer treatment Research to be presented at the 2009 American Association of Pharmaceutical Scientists American Association of Pharmaceutical Scientists. New research to be presented in November at the American Association of Pharmaceutical Scientists AAPS Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles TPM have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. Au, Pharm.D., Ph.D., an AAPS fellow and a d...
http://eurekalert.org/pub_releases/2009-11/aaop-dop110209.php
*  Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in tran
... sgenic rodents. BioPortfolio The World's Leading Biotech, Healthcare and Medical Resource. Advanced Search Login Subscribe RSS. Loading. BioPortfolio. Menu. Loading. Topics. All Topics Biotechnology Biotech Business Biotech Products Cancer Cardiovascular Dermatology Drug Discovery Endocrinology Gastroenterology Immunology Infectious Diseases Mental Health Neurology Obstetrics Orthopedics Public Health Respiratory Rheumatology Urology Track topics Track topics important to you. World Biotech and Healthcare News. Publish Your News On BioPortfolio. Search News On BioPortfolio. Latest News. Citations. Search PubMed Research Papers. Latest Research Papers. Research Papers by Journal. Market Reports. Search Life Science Market Reports Store. Recent Market Research Reports added. Channels. Submit or Amend a Product Profile. Search Life Science Channels Database. Recent Technologies, Products and Technologies added. Clinical Trials. Search Clinical Trials. Latest Clinical Trials. Drugs. Search our Drug Database. ...
http://bioportfolio.com/resources/pmarticle/246167/Acinar-to-ductal-Metaplasia-Accompanies-C-myc-induced-Exocrine-Pancreatic-Cancer-Progression.html
*  What is COST of Pancreatic Cancer Surgery in India| Pancreatic Treatment India
What is COST of Pancreatic Cancer Surgery in India. Pancreatic Treatment India. Pancreatic Cancer Treatment and Surgery in India Plan your Pancreatic Cancer Treatment and Surgery in India with Forerunners Healthcare Consultants. Philemon - Kenya Pancreatic Cancer Surgery in India. Cancer of the pancreas may be called pancreatic cancer or carcinoma of the pancreas. What are Symptoms of Pancreatic Cancer. Treatment for these tumors is based on stage of growth. These are almost always benign tumors, which although can grow quite large, do not spread to other parts of the body. These tumors are nearly always benign, meaning non-malignant and non-cancerous. Radiation Therapy for Pancreatic Cancer: Radiation therapy is a cancer treatment that uses high-energy radiation beams to kill cancer cells. In India, there are numerous hospitals available which specializes in different types of cancer treatments including treatment of Pancreatic Cancer. Cities in India that offer Pancreatic Cancer Surgery in India are as foll...
http://forerunnershealthcare.com/pancreatic-cancer-treatment-surgery-India-low-cost-benefits.html
*  Innovative Clinical Trial for Advanced Pancreatic Cancer Patients | Cancer Network
Innovative Clinical Trial for Advanced Pancreatic Cancer Patients. Cancer Network. Skip to main content. Search For... Search. Cancer Network SearchMedica. Topics: ARS 2015. Breast Cancer. Colorectal Cancer. Leukemia Lymphoma. Lung Cancer. Melanoma. Prostate Cancer. Browse All Topics All Topics ARS 2015 Breast Cancer Colorectal Cancer Leukemia & Lymphoma Lung Cancer Melanoma Prostate Cancer. MAIN MENU Home ONCOLOGY Cancer Management Handbook News Blogs Topics Image IQ Podcasts Conferences. Welcome Guest. Login or Register Welcome My Account. My Account or Logout. Connect to other sites within the UBM Medica Network. ubmslateCN-logo-ubm. ≡. Search For... Search. Cancer Network SearchMedica. Topics: ARS 2015. Breast Cancer. Colorectal Cancer. Leukemia Lymphoma. Lung Cancer. Melanoma. Prostate Cancer. Browse All Topics All Topics ARS 2015 Breast Cancer Colorectal Cancer Leukemia & Lymphoma Lung Cancer Melanoma Prostate Cancer. Main menu Home. Topics. Buyer s Guide. Journal. MAIN MENU Home ONCOLOGY Cancer ...
http://cancernetwork.com/articles/innovative-clinical-trial-advanced-pancreatic-cancer-patients
*  Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G
... 1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 -- Gansauge et al. 9 8 : 611 -- Cell Growth & Differentiation. Your browser does not support frames. Click here to view the unframed reprint....
http://cgd.aacrjournals.org/cgi/reprint/9/8/611
*  Exocrine pancreatic cancer
... exocrine cancer is a disease in which malignant cancer cells are found in the tissues of the pancreas also called pancreatic cancer external links entry in the public domain nci dictionary of cancer terms category digestive system neoplasia...
https://en.wikipedia.org/wiki/Exocrine_pancreatic_cancer
*  Fox Chase Cancer Center Pancreatic Cancer Treatment
... Jobs. News Publications. Calendar. Contact Us. Appointments. Search. Login Logout. Print this Page A A A Text Size. Home. Why Choose Fox Chase. Patient Center. Learn About Cancer. Types of Cancer Breast Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecological Cancer Head and Neck Cancer Liver Cancer Lung Cancer Hematologic Cancer Melanoma Neuro-Oncology Cancer Prostate Cancer Sarcoma Skin Cancer Cancer Diagnosis & Treatment Find a Clinical Trial Rehabilitation African Americans and Cancer Latino Community and Cancer. Find a Doctor. Prevention, Risk and Screening. Research at Fox Chase. Partner Hospitals. For Health Professionals. Community Health. Giving and Volunteering. Temple Health. Temple University School of Medicine. Temple University. Learn About Cancer. Types of Cancer Gastrointestinal Cancer Pancreatic Cancer Loading the player ... Fox Chase physicians take a team approach to treating cancer. Learn about the team for hepatobiliary and pancreatic cancers. 9 min. The pancreas. The pancre...
http://fccc.edu/cancer/types/gastrointestinal/pancreatic.html
*  Pancreatic Cancer Diagnosis, Treatments & Therapies | CTCA
Pancreatic Cancer Diagnosis, Treatments & Therapies. Call us 24/7 at 800 615-3055 Chat online now. Chat online with us Please enter your first name. Please enter your last name. Seeking care for. Please enter who you are seeking care for. Please enter the type of insurance. Please review the disclaimer. Chat now. Have us call you. Or we can call you. Find Treatments. Become a Patient. Pancreatic cancer symptoms. Pancreatic cancer stages. Diagnostics and treatment options. Diagnostic evaluations. Advanced treatments. Integrative oncology services. Cancer experts. Become a patient. Pancreatic cancer statistics. Pancreatic cancer diagnostics and treatment. At each of our hospitals, you'll find innovative pancreatic cancer treatments and technologies all under one roof. Our pancreatic cancer experts use state-of-the-art diagnostic tools, including advanced imaging and laboratory tests, to evaluate pancreatic cancer. Then together, we develop a comprehensive pancreatic cancer treatment plan that works for you. You...
http://cancercenter.com/pancreatic-cancer/diagnostics-and-treatments/
*  Medical Xpress - pancreatic cancer(... continued page 11)
Medical Xpress - pancreatic cancer ... Home pancreatic cancer. News tagged with pancreatic cancer. 1 week. 1 week. 1 week. Related topics: cancer cells · cancer · pancreas · cancer research · patients. Surgery. Jul 15, 2014 0 0. Cancer. Jul 14, 2014 0 0. Cancer. A vaccine may cause pancreatic cancer to respond to immunotherapy. Medical Xpress —Pancreatic ductal adenocarcinomas PDAC do not typically respond to immunotherapy, which limits treatment options for this cancer. By priming with a therapeutic vaccine and a low-dose chemotherapy combination ... Jul 10, 2014 0 0. Cancer. Central venous catheters up infection risk in cancer patients. HealthDay —Long-term central venous catheters CVCs are associated with an increased risk of infection in older adults with cancer, according to research published online June 30 in the Journal of Clinical Oncology. Jul 03, 2014 0 0. Cancer. Jul 01, 2014 0 1. Cancer. Medical Xpress —Almost 40 per cent of pancreatic cancers – one of the deadliest forms of cancer – could be avo...
http://medicalxpress.com/tags/pancreatic cancer/page11.html
*  Flavonoids of celery, artichokes kill human pancreatic cancer cells - UPI.com
... About Us. UPI en Español. Log in or Register. Top News. U.S. News. World News. Entertainment. Movies. Music. TV. Odd News. The Almanac. Business. Security Industry. Energy Industry. Sports. Science. Health. Analysis. Photos. Latest Photos. News. Entertainment. Sports. Features. Archives. Archive. . Home / Health News Celery, artichokes, oregano kill human pancreatic cancer cells. Aug. 17, 2013 at 2:02 AM Follow @upi. Comments. License Photo. URBANA, Ill., Aug. 17 UPI -- Celery, artichokes and herbs, such as Mexican oregano, contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells, U.S. researchers say. Elvira de Mejia, a professor of food chemistry and food toxicology at the University of Illinois, and Jodee Johnson, a doctoral candidate in de Mejia's lab who has graduated, found using the flavonoids as a pre-treatment before administering a chemotherapeutic drug inhibited an enzyme that facilitated killing human pancreatic cancer cells. "Apigenin alone induced cell death in two ...
http://upi.com/Health_News/2013/08/17/Celery-artichokes-oregano-kill-human-pancreatic-cancer-cells/UPI-83001376719336/?spt=mps&or=2
*  .. Category Archives: Pancreatic Cancer Clinical Trials .. Nanoliposomal Topoisomerase I Inhibitor
Category Archives: Pancreatic Cancer Clinical Trials. Nanoliposomal Topoisomerase I Inhibitor for Advanced Cancer of the Pancreas. By. pancreatica. Published. October 1, 2013. There is no universally agreed upon second line treatment for metastatic pancreatic cancer. On August 20 in the British Journal of Cancer, the results of an interesting international Phase II clinic trial using nanoliposomal irinotecan for the treatment of earlier pre-treated metastatic pancreatic cancer were published. The researchers included Dr. Margaret Tempero, who is on. Also posted in Medical Research, Pancreatic Cancer. Leave a comment. IA and IV Gem and MITO-C. By. pancreatica. Published. September 21, 2013. Recent advances over the drug agent gemcitabine for advanced pancreatic cancer are still in progress but appear to include the FOLFIRINOX 5-FU based combination regimen and now recently Abraxane plus gemcitabine. Now comes a study by German researchers Lorenz and colleagues from the University of Frankfurt as published in t...
http://pancreatica.org/category/pancreatic-cancer-clinical-trials/page/4/
*  Gemcitabine and Erlotinib in Pancreatic Cancer | Oncolink - Cancer Resources
Gemcitabine and Erlotinib in Pancreatic Cancer. Cancer Types. Cancer Types. Bone Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. Pediatric Cancers. Skin Cancers. Cancer Treatment. Phase III trials have looked at the use of combination chemotherapy regimens in the treatment of this disease, but none have been positive for a survival benefit. Gemcitabine intravenous IV chemotherapy has shown improved single agent activity in pancreatic cancer compared to standard 5-fluorouracil 5-FU, with clinical benefit response rates of 24% vs. The authors of this study sought to investigate the use of gemcitabine G and erlotinib E; brand name Tarceva as combination treatment in patients pts with locally advanced LA and metastatic pancreatic cancer. Clinical/Scientific Implications Earlier today 11/2/05, the US Food and Drug Administration FDA announced the approval of erlotinib in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer patients who have not received prior chemothera...
http://oncolink.org/conferences/article.cfm?c=3&s=35&ss=204&id=1337
*  Pancreatic Cancer | Oncolink - Cancer Resources
Pancreatic Cancer. Cancer Types. Cancer Types. Bone Cancers. Brain Tumors. Carcinoid & Neuroendocrine Tumors. Endocrine System Cancers. Gastrointestinal Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. OncoLink Vet. Pediatric Cancers. Skin Cancers. Urinary Tract Cancers. Cancer Treatment. Getting Treatment. Types of Cancer. Gastrointestinal Cancers. Pancreatic Cancer. Pancreatic Cancer. The Etiology of Pancreatic Cancer. High risk in central nervous system, pancreatic, upper gastrointestinal, lung malignancies Feb 25, 2011 High risk in central nervous system, pancreatic, upper gastrointestinal, lung malignancies. Blood test for antigen in pancreatic cancer, genetic variation in gastric cancer studied Jan 26, 2010 Blood test for antigen in pancreatic cancer, genetic variation in gastric cancer studied. Oral Microflora Tied to Chronic Pancreatitis, Pancreatic Cancer Oct 18, 2011 Salivary microflora potential biomarker for pancreatic cancer, chronic pancreatitis. Pancreatic Cancer and Genetics Chemoeboliz...
http://oncolink.org/experts/experts1.cfm?c=45
*  BMS-247550 in Treating Patients With Advanced Pancreatic Cancer - Full Text View - ClinicalTrials.go
... v. BMS-247550 in Treating Patients With Advanced Pancreatic Cancer This study has been completed. Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute NCI Information provided by: National Cancer Institute NCI. ClinicalTrials.gov Identifier: NCT00016965 First received: June 6, 2001 Last updated: June 20, 2013 Last verified: April 2003 History of Changes. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer. Pancreatic Cancer. Further study details as provided by National Cancer Institute NCI :. PRIOR CONCURRENT THERAPY: Biologic therapy: No prior neoadjuvant, adjuvant, or primary immunotherapy for advanced pancreatic cancer No concurrent anticancer immunotherapy. Chemotherapy: No prior neoadjuvant, adjuvant, or primary chemotherapy for advanced pancreatic cancer No other concurrent anticancer chemotherapy. Endocrine therapy: No prior neoadjuvant, adjuvant, or primary hormonal therapy for advanced pancreatic cancer No...
https://clinicaltrials.gov/show/NCT00016965
*  .. This week in PLoS Medicine: Six-gene predictor in pancreatic cancer treatment; Reviews for devic
← Reducing bias in systematic reviews – a bid for registration UNAIDS' Outlook →. This week in PLoS Medicine: Six-gene predictor in pancreatic cancer treatment; Reviews for devices; Evidence-based policy in Africa By PLOS Medicine Posted: July 13, 2010. Image credit: George Gastin. Three new articles were published this week in PLoS Medicine : Jen Jen Yeh and colleagues developed and validated a six-gene signature in patients with pancreatic ductal adenocarcinoma that may be used to better stage the disease in these patients and assist in treatment decisions. Using examples from recent FDA regulatory proceedings, Jonas Hines and colleagues critique the medical device premarket review and identify eight weaknesses in the process that should be remedied. Lastly, as part of our continuing series on maternal, neonatal, and child health in sub-Saharan Africa, Igor Rudan and colleagues discuss various priority-setting tools for health care and research that can help develop evidence-based policy. See the earlier bl...
http://blogs.plos.org/speakingofmedicine/2010/07/13/this-week-in-plos-medicine-six-gene-predictor-in-pancreatic-cancer-treatment-reviews-for-devices-evidence-based-policy-in-africa/
*  Old Drug Extends Life For Pancreatic Cancer Patients | KANW
Old Drug Extends Life For Pancreatic Cancer Patients. KANW. Program Underwriting. Program Guide. PSA Policy. Program Underwriting. Program Guide. PSA Policy. Old Drug Extends Life For Pancreatic Cancer Patients By. A two-drug combination extends life for such patients compared to standard chemotherapy. "There's a chance to make it to two years and as we follow patients, some may make it to three years," study author Dr. The latest study, involving nearly 900 patients, gave half Abraxane in combination with gemcitabine, the standard chemotherapy for pancreatic cancer. The midpoint survival of those who got the two-drug combo was 8.5 months compared to 6.7 months for standard chemo. Perhaps more significant, 35 percent of the two-drug group were alive a year later, compared to 22 percent of the others. And 9 percent survived at least 2 years, versus 4 percent who got only gemcitabine. "Every single patient in the clinic will be asking about it — and there are a lot of people out there with pancreatic cancer." S...
http://kanw.com/post/old-drug-extends-life-pancreatic-cancer-patients
*  Pancreatoblastoma
... infobox disease name pancreatoblastoma image caption diseasesdb icd icd icdo omim medlineplus emedicinesubj emedicinetopic meshid pancreatoblastoma is a rare type of pancreatic cancer it occurs mainly in childhood and has a relatively good prognosis symptoms pathology treatment references symptoms children with pancreatoblastoma rarely present with early stage disease instead most present with locally advanced or metastatic disease common presenting symptoms include abdominal pain emesis and jaundice a multidisciplinary approach including good clinical history state of the art imaging and careful pathology is often needed to establish the correct diagnosis pathology resected pancreatoblastomas can be quite large ranging from centimeters to centimeters in size to inches they are typically solid soft masses under the microscope at least two cell types are seen cells with acinar differentiation and cells forming small squamoid nests the cells with acinar differentiation have some features of the normal acin...
https://en.wikipedia.org/wiki/Pancreatoblastoma
*  Gemcitabine and Erlotinib in Pancreatic Cancer | Oncolink - Cancer Resources
Gemcitabine and Erlotinib in Pancreatic Cancer. Cancer Types. Cancer Types. Bone Cancers. Head and Neck Cancers. Skin Cancers. Phase III trials have looked at the use of combination chemotherapy regimens in the treatment of this disease, but none have been positive for a survival benefit. Gemcitabine intravenous IV chemotherapy has shown improved single agent activity in pancreatic cancer compared to standard 5-fluorouracil 5-FU, with clinical benefit response rates of 24% vs. Clinical/Scientific Implications Earlier today 11/2/05, the US Food and Drug Administration FDA announced the approval of erlotinib in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer patients who have not received prior chemotherapy. Erlotinib is the first drug to show a significant overall survival improvement when used with gemcitabine chemotherapy as initial treatment for pancreatic cancer in a phase III setting. Drug Ups Effect of Gemcitabine in Pancreatic Cancer Feb 29, 2012 Nanoparticle al...
http://oncolink.org/conferences/article.cfm?id=5875
*  Pancreatic Cancer Research - Lustgarten Foundation
... Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Travel & Housing Assistance. Legal Assistance & Advocacy. Being a Caregiver. Pancreatic Cancer Resources. Pancreatic Cancer Facts. Pancreas Cancer-Specific Resources. Patient Medical Expenses. Legal Assistance & Advocacy. Travel & Housing As...
http://lustgarten.org/precursorlesionsequencinginitiative
*  Pancreatic Cancer Resources - Pancreatic Cancer Research - Lustgarten Foundation
... Skip to main content. Donate Now. Calendar. Join Our Email List. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Home. Site Map. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. What are the Treatment Options. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Gathering Information and Making Informed Decisions. Tips for your Doctor Visit. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Establishing Suppor...
http://lustgarten.org/pancreascancerspecificresources
*  Party in the Penthouse Event Details - Pancreatic Cancer Research - Lustgarten Foundation
... Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Site Map. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Travel & Housing Assistance. Legal Assistance & Advocacy. Pancreatic Cancer Resources. Pancreatic Cancer Facts. Pancreas Cancer-Specific Resources. Patient Medical Expenses. Legal Assistance & Advocacy. ...
http://lustgarten.org/party-in-the-penthouse/party-in-the-penthouse-event-details
*  Get Research Information - Pancreatic Cancer Research - Lustgarten Foundation
... Calendar. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Travel & Housing Assistance. Legal Assistance & Advocacy. Pancreatic Cancer Resources. Pancreatic Cancer Facts. Pancreas Cancer-Specific Resources. Clinical Trials. Patient Medical Expenses. Legal Assist...
http://lustgarten.org/page.aspx?pid=691
*  Pancreatic Cancer | NewYork-Presbyterian/Weill Cornell
Pancreatic Cancer. NewYork-Presbyterian/Weill Cornell. Advanced Interventional Endoscopy. The Pancreas Program. Pancreatic Cancer The Pancreas Program. Pancreatic Cancer. The Pancreas Program >. Pancreatic Cancer. This is the approach taken by experts in the Pancreas Program at the Center for Advanced Digestive Care of NewYork-Presbyterian/Weill Cornell Medical Center. Our team is also conducting clinical trials of promising new therapies to improve pancreatic cancer prognosis. Pancreatic Cancer Risk Factors Several factors have been shown to raise the risk of pancreatic cancer. Symptoms of Pancreatic Cancer When located in the tail or body of the pancreas, symptoms of pancreatic cancer may include abdominal pain. The following diagnostic tests may be performed by our Advanced Endoscopy Team to diagnose and stage the disease: Confocal endomicroscopy: The CADC is the only center in the country to offer confocal endomicroscopy of the pancreas, which can aid in the detection and staging of pancreatic cancer. To ...
http://cadc.nyp.org/our-services/pancreatic-program/pancreatic-cancer.html
*  Types of treatment for pancreatic cancer | Cancer Research UK
Pancreatic cancer About pancreatic cancer The pancreas Causes Screening Symptoms Types Seeing a specialist What to ask Diagnosing pancreatic cancer Tests Biopsy Further tests What to ask Treating pancreatic cancer Stages Outlook and stats Treatment types Surgery Types of surgery Removing the cancer Relieving symptoms Having surgery What to ask Chemotherapy Radiotherapy Advanced cancer What it is Drugs Radiotherapy Stents Pain control What to ask Follow up Research What to ask Living with pancreatic cancer Coping Diet Advanced cancer What to ask About this section Organisations Reading list Pancreatic cancer clinical trials Pancreatic cancer questions and answers. A quick guide to what's on this page Surgery to remove pancreatic cancer Surgery to relieve symptoms Using stents to relieve symptoms. Types of treatment for pancreatic cancer The type of treatment you have depends on your type of pancreatic cancer, how far it has spread the stage, and your general health and level of fitness. Surgery or stents to re...
http://cancerresearchuk.org/about-cancer/type/pancreatic-cancer/treatment/which-treatment-for-pancreatic-cancer
*  Treatments | Pancreatic Cancer UK
Treatments. Pancreatic Cancer UK. Login to Pancreatic Cancer UK. Username. Password. Register Forgotten password. Login. Decrease font size Increase font size Reset font size Standard Contrast High Contrast Blue/Black Contrast Cream/Black Contrast. About us Press office Contact us Health professionals. Pancreatic Cancer UK. Follow Us:. Join Pancreatic Cancer UK on Facebook Join Pancreatic Cancer UK on Twitter Join Pancreatic Cancer UK on YouTube. Search. Menu. Home. Information and support. Just diagnosed. Get support. Facts about pancreatic cancer. Treatments for pancreatic cancer. Managing diet symptoms. Living with pancreatic cancer. Our publications. Real life stories. Join our Discussion Forum. Research. Research we fund. Apply for a research grant. Our Policies Advisory Board. Campaigning and volunteering. Get involved. Policy and campaigning. Fundraising and events. Join an event. Plan your own event. I have a place in an event. In Memory and legacy giving. Corporate fundraising. Special events. Fundra...
http://pancreaticcancer.org.uk/information-and-support/treatments-for-pancreatic-cancer
*  Pancreatic Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI]
Pancreatic Cancer Treatment PDQ® : Treatment - Health Professional Information. find a physician. Bon Secours Medical Group. find a facility. ST. FRANCIS downtown. ST. FRANCIS eastside. ST. FRANCIS millennium. St. Francis Outpatient Surgery Centers. St. Francis Cancer Center. Urgent Care Facilities. Pearlie Harris Center for Breast Health. St. Francis Therapy Centers. St. Francis HomeCare. Open Arms Hospice. our services. back and neck pain treatment. breast health center. business health services. cancer care. diabetes services. fibromyalgia care. geriatric consultations. healThy self fitness weight loss. heart care. homecare. imaging and diagnostics. nutrition counseling. obstetrics. Open Arms Hospice. orthopedics. palliative care. rehabilitation services. sinus surgery. sleep center. surgical care. surgical weight loss program. urgent care. women's care. wound healing. patients visitors bill payment. hospital bills insurance. financial assistance. advance directives. patient rights. patient information. yo...
http://stfrancishealth.org/health-library.html?documentID=ncicdr0000062951
*  Anti-K-Ras siRNA to Treat Pancreatic Cancer
... Contact. Site Map. Mission Charter. NSTI Team. Nanotech Conference. Nanotech Database. Publications. Courses. Nanotechnology Short Courses. Events. Past Events. Publications. Nanotech 2014 Vol. 1 Nanotech 2014 Vol. 2 Nanotech 2014 Vol. 3 Nanotech 2013 Vol. 1 Nanotech 2013 Vol. 2 Nanotech 2013 Vol. 3 Nanotech 2012 Vol. 1 Nanotech 2012 Vol. 2 Nanotech 2012 Vol. 3 Older NSTI Publications. Index of Authors. Index of Keywords. Order Form. Courses. News. Nano World News. Austin, TX, December 1-3, 2015. Austin, TX, December 1-3, 2015. NSTI Online Community. Nanotech 2010 Vol. Chapter 6: Cancer Nanotechnology. Anti-K-Ras siRNA to Treat Pancreatic Cancer. Authors: D.C. Keywords: pancreatic cancer, K-Ras, siRNA. Chemotherapeutic drugs used to treat pancreatic cancers are toxic and minimally effective, yielding a 1-4% 5-year survival rate after initial diagnosis. Approximately 90% of pancreatic cancers possess point mutations in the K-Ras proto-oncogene. Point mutations in the K-Ras gene cause the K-Ras protein to ...
http://nsti.org/procs/Nanotech2010v3/6/W50.305
*  Postoperative complications and survival rates for pancreatic cancer patients.
... BioMedSearch. Advanced Search. Tools. Search Tutorial. Login. Create Free Account. Document Detail. Postoperative complications and survival rates for pancreatic cancer patients. MedLine Citation:. PMID: 21253778 Owner: NLM Status: Publisher. BACKGROUND/AIMS: Surgical resection offers the only potential cure for pancreatic tumor. The goal of the present study is to determine complications associated with pancreatic resection and to describe their influence on the survival rate for pancreatic cancer patients. MATERIALS AND METHODS: Between 1996 and 2009, the findings of 125 pancreatic cancer patients were analyzed in a prospective trial at the First Department of Surgery, University Hospital in Košice, Slovakia. RESULTS: The overall mortality rate and morbidity rate were 3.2% 4 patients and 27% 34 patients, respectively. In patients with postoperative complications, the median survival time was 12 months range, 8-14 months, in patients without complications - 18 months range, 15-20 months. CONCLUSION: The...
http://biomedsearch.com/nih/Postoperative-complications-survival-rates-pancreatic/21253778.html
*  Rocking the Foundation Landing Page - Pancreatic Cancer Research - Lustgarten Foundation
... Calendar. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Travel & Housing Assistance. Legal Assistance & Advocacy. Pancreatic Cancer Resources. Pancreatic Cancer Facts. Pancreas Cancer-Specific Resources. Patient Medical Expenses. Legal Assistance & Advocacy. ...
http://lustgarten.org/rocking-the-foundation-landing-page
*  Pancreatic Cancer Research - Lustgarten Foundation
... Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Travel & Housing Assistance. Legal Assistance & Advocacy. Being a Caregiver. Pancreatic Cancer Resources. Pancreatic Cancer Facts. Pancreas Cancer-Specific Resources. Patient Medical Expenses. Legal Assistance & A...
https://lustgarten.org/sslpage.aspx?pid=857&bm=-108994014
*  Flavonoids of celery, artichokes kill human pancreatic cancer cells - UPI.com
... Top News. News. World News. Odd News. Security Industry. Energy Industry. News. Home / Health News Celery, artichokes, oregano kill human pancreatic cancer cells. 17, 2013 at 2:02 AM Follow @upi. 17 UPI -- Celery, artichokes and herbs, such as Mexican oregano, contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells, U.S. Elvira de Mejia, a professor of food chemistry and food toxicology at the University of Illinois, and Jodee Johnson, a doctoral candidate in de Mejia's lab who has graduated, found using the flavonoids as a pre-treatment before administering a chemotherapeutic drug inhibited an enzyme that facilitated killing human pancreatic cancer cells. But we received the best results when we pre-treated cancer cells with apigenin for 24 hours, then applied the chemotherapeutic drug gemcitabine for 36 hours," de Mejia said in a statement. In one of the cancer cell lines, the percentage of cells undergoing apoptosis went from 8.4 percent in cells that had not been treated wit...
http://upi.com/Health_News/2013/08/17/Celery-artichokes-oregano-kill-human-pancreatic-cancer-cells/UPI-83001376719336/?spt=mps&or=1
*  .. An Intro to Pancreatic Cancer Part II: Prevention, Diagnosis & Treatment .. Steve Jobs, Pancreat
An Intro to Pancreatic Cancer Part II: Prevention, Diagnosis Treatment. Last week, we gave you an intro to Pancreatic Cancer , including statistics, information on the types of pancreatic cancer, and pancreatic cancer risk factors. Pancreatic Cancer Prevention. Diagnosing Cancer of the Pancreas. The whipple procedure can be used when the cancer is in the head of the pancreas and involves the removal of the head of the pancreas and parts of the bile ducts, small intestine, and stomach; distal pancreatectomy removes the body and tail of the pancreas and the spleen; and total pancreatectomy removes the entire pancreas, part of the small intestine, a portion of the stomach, the common bile duct, the gallbladder, the spleen, and nearby lymph nodes. Chemotherapy – Chemotherapy is medication delivered to the body to eliminate cancer cells or greatly reduce their effect. Radiation Therapy – Radiation therapy is a type of cancer treatment that uses ionizing radiation energy to kill cancer cells and shrink cancerous tu...
http://advancingyourhealth.org/cancer/tag/whipple-procedure/
*  Pancreatic Cancer News -- ScienceDaily
... Your source for the latest research news. Mobile. Follow. Subscribe. Breaking News :. Rocks Show First Photosynthesis That Made Oxygen. Understanding Others' Thoughts Helps Kids to Lie. Extremely Light Storage Device as E-Car Battery. Birds Flew Over the Heads of Dinosaurs. Hog-Nose Rat Discovered. Foot Fossil: Evolutionary Messiness of Walking. Migrating Songbirds Can Be Tricked by Magnets. Fossils Intensify Mystery of Odd Toothy Mammal. Predator Survives, but Ecosystem Crashes. Restoring Vision With Stem Cells. Pancreatic Cancer News October 7, 2015. DNA Building Blocks: Cancer's Achilles Heel. New Compounds Shrink Pancreatic Cancer Tumors. Bacterial Communication System to Stop Cancer. 3-D Method Used to Grow Miniature Pancreas. Latest Headlines updated 3:22am EDT. Potential Source of Insulin-Producing Cells Found in Adult Human Pancreas. Sep. 23, 2015 Cells that express neurogenin 3 may one day be harnessed to create a plentiful supply of insulin-producing beta cells for the treatment of diabetes, a ...
http://sciencedaily.com/news/health_medicine/pancreatic_cancer/
*  Clinical Trial Failures Further Signal Pancreatic Cancer’s Intractable Nature | Insight & Intel
FDA Nominee Driven by "Data, Data, Data". More GEN Exclusives ». Jobs Report: Data, Business, and Regulatory ... FDA Nominee Driven by "Data, Data, Data". More GEN Exclusives ». Market & Tech An... GEN Exclusives More. GEN Exclusives More » Sep 25, 2009 Clinical Trial Failures Further Signal Pancreatic Cancer’s Intractable Nature Researchers need to step out of the gemcitabine box and also take on the development of diagnostics for early detection. Single-agent gemcitabine thus remains the standard treatment for advanced pancreatic cancer. Even as clinical researchers throw more combinations of drugs at the disease as first- or second-line therapies, pancreatic cancer remains the fourth leading cause of cancer deaths in the U.S. Due to difficulties in diagnosis, the aggressive nature of pancreatic cancer, and the limited systemic treatments available, the five-year survival rate for patients who have pancreatic adenocarcinoma remains at only about 5%. Oncologists treating this disease say early diagnosis is c...
http://genengnews.com/insight-and-intelligenceand153/clinical-trial-failures-further-signal-pancreatic-cancer-s-intractable-nature/63659966/?kwrd=Pfizer
*  foodconsumer.org - Cigarette smoking may boost pancreatic cancer risk - study
... Nutrition. Avoiding Illness. Safety. Environment. Food Chemicals. Cooking Dining. Shopping. Sci-Tech. Politics. Opinion. Non-food. Watch-List. . Search. Home. Avoiding Illness. Cancer. Cigarette smoking may boost pancreatic cancer risk - study. Cigarette smoking may boost pancreatic cancer risk - study. 10/31/2010 15:48:00 admin. Exposure to cigarette smoke may boost risk of pancreatic cancer, a study published in the June 2010 issue of Cancer Epidemiology, Biomarkers Prevention suggests. The study showed current smokers and former smokers were 82 percent and 34 percent increased risk of pancreatic cancer respectively, compared to never cigarette smokers. Mirjam M. Heinen at Maastricht University Medical Centre and colleagues examined the effect of active cigarette smoking, smoking cessation and passive smoking on the risk of pancreatic cancer in 120,852 men and women who completed a baseline questionnaire in 1986. During the 16.3 years of follow-up, 520 cases of pancreatic cancer were identified. The re...
http://foodconsumer.org/newsite/mobile/2/Cancer/cigarette_smoking_may_boost_pancreatic_cancer_risk_3110100949.html
*  .. Pancreatic Cancer News & Journal Articles .. About aspenbio .. News .. Articles .. Share this:
← Learning More About Pathways Latest Pancreatic Cancer News Journal Articles →. Pancreatic Cancer News Journal Articles Posted on. Nuvilex discusses Cell-in-a-Box technology used for pancreatic cancer clinical trial Nuvilex, Inc. NCKU Signs MOU with OSU on Cancer Research – Business Wire – SunHerald.com National Cheng Kung University NCKU in Tainan, southern Taiwan, signed a memorandum of understanding MOU with the Ohio State University OSU College of Pharmacy on March 20 at the NCKU College of Medicine as part of its effort to enhance its international academic cooperation … Viruses kill pancreatic tumors in preclinical model About 95 percent of pancreatic cancers are pancreatic ductal adenocarcinomas PDAs. Mouse ‘avatars’ could aid pancreatic cancer therapy : Nature News Comment Mouse ‘avatars’ could in future allow physicians to find the most effective cocktail of cancer drugs to combat a particular tumour before giving them to a patient, according to researchers at the annual meeting of the Human Genome ...
https://aspenbio.wordpress.com/2012/03/25/pancreatic-cancer-news-journal-articles/
*  Facebook Ask an Expert December 2012 - Pancreatic Cancer Research - Lustgarten Foundation
... Skip to main content. Donate Now. Calendar. Join Our Email List. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Home. Site Map. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. What are the Treatment Options. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Gathering Information and Making Informed Decisions. Tips for your Doctor Visit. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Establishing Suppor...
http://lustgarten.org/facebook-ask-an-expert-december-2012
*  Pancreatic Cancer Research - Lustgarten Foundation
... Skip to main content. Donate Now. Calendar. Join Our Email List. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Home. Site Map. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. What are the Treatment Options. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Gathering Information and Making Informed Decisions. Tips for your Doctor Visit. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Establishing Suppor...
http://lustgarten.org/page.aspx?pid=977
*  Pancreatic Cancer Research - Lustgarten Foundation
... Skip to main content. Donate Now. Calendar. Join Our Email List. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Home. Site Map. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. What are the Treatment Options. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Gathering Information and Making Informed Decisions. Tips for your Doctor Visit. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Establishing Suppor...
http://lustgarten.org/pancreaticcancertreatmentcenters
*  Pancreatic Cancer Research - Lustgarten Foundation
... Skip to main content. Donate Now. Calendar. Join Our Email List. Cablevision s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Home. Site Map. Get Informed. About Pancreatic Cancer. Symptoms of Pancreas Cancer. Types of Pancreas Cancer. Stages of Pancreas Cancer. Myths and Facts about Pancreas Cancer. Pancreas Cancer Library. What is Pancreatic Cancer. What is the Pancreas. What are the Different Types of Pancreatic Cancer. What Causes Pancreatic Cancer. What is Hereditary Pancreatic Cancer. What are the Symptoms of Pancreatic Cancer. How is Pancreatic Cancer Diagnosed. What are the Stages of Pancreatic Cancer. What are the Treatment Options. How can Pancreatic Cancer be Prevented. About Your Diagnosis of Pancreas Cancer. Gathering Information and Making Informed Decisions. Tips for your Doctor Visit. Your Rights as a Patient and Informed Consent. Advocacy. Finding Your Medical Care Team. Finding a Treatment Center. Establishing Suppor...
https://lustgarten.org/sslpage.aspx?pid=857&bm=818534570
*  The Life Extension Blog: Antioxidants Found to Reduce Pancreatic Cancer Risk
... Antioxidants Found to Reduce Pancreatic Cancer Risk. Possible early symptoms that should be evaluated by your physician are:. Almost all patients with pancreatic cancer are older than 55 years and more than 70 percent are older than 65 years. A recent study shows that dietary antioxidants could significantly reduce your risk of developing pancreatic cancer. This increased to 86 people within 17 years of starting the study. Those in the top 25% of selenium intake had half the risk of developing pancreatic cancer than those in the lowest 25% of intake. People with the highest intake of vitamins C, E and selenium were 67% less likely to develop pancreatic cancer than people with the lowest intake. Labels: Antioxidants, cancer, Nutrition, Pancreatic cancer, Prevention, selenium, Supplements, Vitamin C, Vitamin E. Life Extension said... I think that since it is pancreatic cancer awareness month, it is important to spread the word about new advancements in pancreatic cancer treatments and diagnosis. LifeExtens...
http://blog.lifeextension.com/2012/08/antioxidants-reduce-pancreatic-cancer.html
*  Daily Radiation | Oncolink - Cancer Resources
Daily Radiation. Oncolink - Cancer Resources. Cancer Types. Cancer Types. Bone Cancers. Brain Tumors. Breast Cancer. Endocrine System Cancers. Gastrointestinal Cancers. Gynecologic Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. Lymphomas. OncoLink Vet. Pediatric Cancers. Skin Cancers. Testicular Cancer. Urinary Tract Cancers. Cancer Treatment. Getting Treatment. Radiation. Support. OncoLink University. Frequently Asked Questions. Cancer Resources. Brown Bag Chat. Daily Radiation OncoLink Last Modified: May 8, 2012. Oral Microflora Tied to Chronic Pancreatitis, Pancreatic Cancer Oct 18, 2011 Salivary microflora potential biomarker for pancreatic cancer, chronic pancreatitis. Irreversible Electroporation Promising in Pancreatic Cancer Sep 7, 2015 Study found procedure improved survival for people with stage III disease. Enoxaparin Prevents VTEs in Advanced Pancreatic Cancer May 21, 2015 Enoxaparin effective for preventing VTEs with no adverse effect on major bleeding, chemo efficacy. Pancreatic Cancer ...
https://oncolink.org/experts/article.cfm?aid=3984&id=3067&c=125
*  Cancer Treatment and Workplace Disclosure | Oncolink - Cancer Resources
Oncolink - Cancer Resources. Cancer Types. Cancer Types. Bone Cancers. Brain Tumors. Breast Cancer. Gastrointestinal Cancers. Gynecologic Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. OncoLink Vet. Pediatric Cancers. Skin Cancers. Testicular Cancer. Urinary Tract Cancers. Cancer Treatment. Getting Treatment. Frequently Asked Questions. Cancer Resources. Cancer Treatment and Workplace Disclosure OncoLink Last Modified: May 8, 2012. For more great information about working with or after cancer diagnosis and treatment I recommend two great resources Cancer and Careers. Oral Microflora Tied to Chronic Pancreatitis, Pancreatic Cancer Oct 18, 2011 Salivary microflora potential biomarker for pancreatic cancer, chronic pancreatitis. Enoxaparin Prevents VTEs in Advanced Pancreatic Cancer May 21, 2015 Enoxaparin effective for preventing VTEs with no adverse effect on major bleeding, chemo efficacy. Pancreatic Cancer and Genetics Pancreatic Enzymes and Suggested Doses When to Take Pancreatic Enzymes Weight los...
http://oncolink.org/experts/article1.cfm?id=3078&c=125
*  Dietary Recommendations after Esophageal Cancer Treatment | Oncolink - Cancer Resources
Oncolink - Cancer Resources. Cancer Types. Cancer Types. Bone Cancers. Brain Tumors. Breast Cancer. Endocrine System Cancers. Gastrointestinal Cancers. Gynecologic Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. Lymphomas. Pediatric Cancers. Skin Cancers. Testicular Cancer. Urinary Tract Cancers. Cancer Treatment. Frequently Asked Questions. Cancer Resources. Brown Bag Chat. Dietary Recommendations after Esophageal Cancer Treatment OncoLink Last Modified: May 8, 2012. Oral Microflora Tied to Chronic Pancreatitis, Pancreatic Cancer Oct 18, 2011 Salivary microflora potential biomarker for pancreatic cancer, chronic pancreatitis. Enoxaparin Prevents VTEs in Advanced Pancreatic Cancer May 21, 2015 Enoxaparin effective for preventing VTEs with no adverse effect on major bleeding, chemo efficacy. Pancreatic Cancer and Genetics Pancreatic Enzymes and Suggested Doses When to Take Pancreatic Enzymes Weight loss and Pancreatic Cancer "Warning Signs" of Pancreatic Cancer Hospice Care for Pancreatic Cancer Pancre...
http://oncolink.org/experts/article.cfm?aid=3994&id=3077&c=125
*  Risk Factors for Pancreatic Cancer - Baylor Scott & White Health
Risk Factors for Pancreatic Cancer - Baylor Scott White Health. > Risk Factors for Pancreatic Cancer. Risk Factors for Pancreatic Cancer. A risk factor is something about you that increases your chance of getting a disease or having a certain health condition. Risk factors do not mean that you will get the disease. Many people who have these risk factors do not develop the disease and many who develop the disease did not have any of these risk factors. The precise cause of all pancreatic cancers is not known and most cases of the disease are sporadic. Age Pancreatic cancer is more common in people age 55 and older. Smoking People who smoke are two to three times more likely to develop pancreatic cancer. People who have diabetes are at greater risk of developing pancreatic cancer. Family history Pancreatic cancer does run in some families. People with a first-degree relative, such as mother or brother, diagnosed with this disease are more likely to get it themselves. Hereditary Risk Factors for Pancreas Cancer...
http://sw.org/cancer-institute/gastrointestinal/pancreas/pancreatic-cancer-risk-factors
*  .. Saliva Biomarkers for Detection of Pancreatic Cancer .. Recent Posts .. Categories .. Monthly Ar
Saliva Biomarkers for Detection of Pancreatic Cancer. By. pancreatica. Published. June 23, 2013. A long friend of the mission of our foundation, Al Laporta, DDS of New Your who lost his beloved mother to pancreatic cancer reminds us of intriguing work by physician and dentist researchers at UCLA demonstrating proof of concept work published in 2010 in the journal Gastroenterology which identified 12 salivary messenger RNA biomarkers that gave a high specificity 95% and sensitivity 90% for the diagnosis of pancreatic cancer. . A diagnostic test based on this work would be noninvasive. . More here. . . . Dale O’Brien, MD. This article was posted in Pancreatic Cancer. Bookmark the permalink. Post a Comment or leave a trackback: Trackback URL. ← Oral thymidylate synthase inhibitor as an Oral Alternative to Gemcitabine. Radiation Dosage May Affect Survival in Adjuvant Therapy in Pancreatic Cancer →. Recent Posts. Pancreatic Cancer Work-up That Includes a Fine Needle Biopsy placed via endoscope locating ultra-sou...
http://pancreatica.org/saliva-biomarkers-for-detection-of-pancreatic-cancer/
*  Pancreatic cancer: Europe's 4th biggest cancer killer · Pancreatic Cancer ActionPancreatic cancer:
Pancreatic cancer: Europe s 4th biggest cancer killer Pancreatic Cancer Action. Pancreatic cancer: Europe s 4th biggest cancer killer Pancreatic Cancer Action. Pancreatic Cancer Action. Pancreatic Cancer. What is pancreatic cancer. Donate. Awareness Month. News. Pancreatic cancer in the news. Supporter news. Search website Donate. Pancreatic cancer: Europe s 4th biggest cancer killer. Pancreatic cancer is the only cancer which has not seen an improvement in European mortality figures for both men and women, a new study published this week in the Annals of Oncology 1 has found. Figures show that although more people are developing cancer because people are living longer overall, fewer are dying from the disease. The exceptions to this are for pancreatic cancer in both men and women and for lung cancer in women, thought to be due to huge rises of female smokers in the 1960 s and 1970 s. The study also confirmed that pancreatic cancer is the fourth leading cause of cancer death in Europe although it remains the ...
https://pancreaticcanceraction.org/news/pancreatic-cancer-europes-4th-biggest-cancer-killer/
*  AFP Documents with MESH term: Pancreatic Neoplasms - American Family Physician
... Advertisement. Items in AFP with MESH term: Pancreatic Neoplasms. Pancreatic Cancer: Diagnosis and Management - Article ABSTRACT: Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country. The overall five-year survival rate is 4 percent, and localized, resectable disease has only a 17 percent survival rate. Risk factors include smoking, certain familial cancer syndromes, and familial chronic pancreatitis. The link between risk of pancreatic cancer and other factors e.g., diabetes, obesity is less clear. Epigastric or back pain, vague abdominal symptoms, and weight loss also are characteristic of pancreatic cancer. More than one half of cases have distant metastasis at diagnosis. Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure. For nonresectable tumors, chemotherapy with gemcitabine prolongs survival. Pain, Depression and Survival - Editorials. ...
http://aafp.org/afp/viewRelatedDocumentsByMesh.htm?meshId=D010190
*  A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least
... 2 Prior Therapies. A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. 90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Drug: 90Y-hPAM4 Drug: 90Y-hPAM4 + gemcitabine. MedlinePlus related topics: Cancer Pancreatic Cancer Drug Information available for: Gemcitabine Gemcitabine hydrochloride Genetic and Rare Diseases Information Center resources: Pancreatic Cancer U.S. Primary Outcome Measures: Safety change in hematology and chemistry laboratory values from baseline Acute safety will be assessed weekly for the 1st 12 weeks, and then for up to 1 year after completion of study drug treatment. Experimental: 90Y-hPAM4 90Y-hPAM4 is administered weekly for 3 weeks. Drug: 90Y-hPAM4 90Y-hPAM4 will be administered weekly for 3 weeks in conjunct...
https://clinicaltrials.gov/ct2/show/NCT01510561?recr=Open&cond="Pancreatic Neoplasms"&rank=13
*  Immunomedics - Clivatuzumab
... Pipeline Epratuzumab 90Y Clivatuzumab Tetraxetan Antibody-Drug Conjugates Early-Stage Pipeline. A prior Phase I single dose-escalation study of 90 Y Clivatuzumab tetraxetan in treatment-relapsed pancreatic cancer patients has also produced encouraging results, with evidence of objective responses. Our current study is a Phase Ib/II fractionated dose-escalation trial of 90 Y Clivatuzumab tetraxetan in combination with gemcitabine for the treatment of patients with newly diagnosed, inoperable, untreated, stage III or stage IV cancer of the pancreas. Advanced Pancreatic Cancer Clivatuzumab tetraxetan is being evaluated as a frontline therapy for patients with advanced, inoperable pancreatic cancer. For more information on this clinical trial, please visit clinicaltrials.gov References Fractionated radioimmunotherapy with 90Y-Clivatuzumab tetraxetan 90Y-hPAM4 plus gemcitabine Gem in advanced pancreatic cancer APC. Goldenberg. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab tetraxetan: a phas...
http://immunomedics.com/clivatuzumab.shtml
*  Molecular marker from pancreatic 'juices' helps identify pancreatic cancer
... Cancer. May 20, 2013 Molecular marker from pancreatic 'juices' helps identify pancreatic cancer May 20, 2013 Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic "juices" can identify almost all cases of pancreatic cancer, their study shows. "While we know more research is needed, including validation of our findings, we can't help but be excited about this advance." Pancreatic cancer and chronic pancreatitis both produce the same signs of disease in the pancreas , such as inflammation, but cancer in the organ is a life-threatening disorder that must be treated immediately and aggressively, Dr. They examined the juice for markers that might distinguish the two disorders, and discovered that the altered gene CD1D, as a single marker, detected 75 percent of patients later diagnosed with pancreatic cancer, but was present in only 9 percent of p...
http://medicalxpress.com/news/2013-05-molecular-marker-pancreatic-juices-cancer.html
*  GEN News Highlights Related To | GEN
The Pons Asinorum of Diagnostic Genomics. FDA Nominee Driven by "Data, Data, Data". Transitioning from Traditional Assay Formats to HTRF Technology. The Pons Asinorum of Diagnostic Genomics. FDA Nominee Driven by "Data, Data, Data". Transitioning from Traditional Assay Formats to HTRF Technology. Molecules Hold the Mirror Up to Cancer. GEN News Highlights Related to Cancer Therapy Deal Worth at Least $50M Phase III Failure for TeloVac Pancreatic Cancer Vaccine TGen, Ventana Team Up in Search of Cancer Biomarkers Scientists Shed New Light on Malignant Pancreatic Cancer Pancreatic Cancer Imaging Agent Earns MabVax $1.75M SBIR Award Hopes Raised for Early Pancreatic Cancer Detection Novel Biomarkers May Detect Pancreatic Cancer at Early Stage Halozyme Halts Phase II Trial of Pancreatic Cancer Drug FDA Halts Trial of Halozyme's PEGPH20 for Pancreatic Cancer Merrimack Eyes NDA for MM-398 after Phase III Success Cancer Research UK, CRT Partner with Astellas to Discover Pancreatic Cancer Treatments RedHill Nabs Opti...
http://genengnews.com/more/related/gen-news-highlights/4/28784/?page=1
*  Pancreatic Cancer | Conditions & Treatments | UCSF Medical Center
Pancreatic Cancer. UCSF Medical Center. About UCSF. Clinical Trials. Getting to UCSF Medical Center. Careers at UCSF Medical Center. Home > Conditions Treatments > Cancer > Pancreatic Cancer. Pancreatic Cancer. Today, UCSF Medical Center is using new technology that's resulting in earlier diagnosis of pancreatic cancer as well as earlier diagnosis of benign cysts, lesions and tumors that could lead to cancer if not treated. Endocrine Pancreas The endocrine pancreas is made up of specialized cells, referred to as islets of Langerhans, that produce hormones. Cancers that begin in islet cells are called islet cell tumors or pancreatic neuroendocrine tumors. At UCSF, we have specialists who conduct research on both types of pancreatic cancers. We have one of the few pancreas cancer research programs in the nation with a team dedicated to learning more about these tumors and developing better treatments. Risk Factors Although the cause of pancreatic cancer is unknown, risk factors have been identified that increas...
http://ucsfhealth.org/conditions/pancreatic_cancer/
*  Pancreatic Cancer Index by MedicineNet.com
... Cancer. Chronic Pain. Diabetes. Health Living. Lung Conditions. Health Living. Featured: Pancreatic Cancer Main Article Pancreatic cancer is a malignant tumor of the pancreas. Pancreatic cancer has been called a "silent" disease because early pancreatic cancer usually does not cause symptoms. Patient Discussions - Viewers share their comments Pancreatic Cancer - Effective Treatments. Picture of Pancreatic Cancer Tumor This is a gross section of a malignant tumor of the pancreas resected from the pancreatic body and tail. Pancreatic Cancer Pictures Slideshow See pictures and read about pancreatic cancer signs, symptoms, causes, statistics, treatment and side effects chemotherapy,... Watch this slideshow to learn which foods and eating strategies may help reduce your risk... Cancer Risk Factors Though it's difficult to say why some people develop cancer while others don't, research shows that certain risk factors increase... Diabetes is a chronic condition characterized by high levels of sugar glucose in t...
http://medicinenet.com/pancreatic_cancer/index.htm
*  Phase I - II Study of Gemcitabine and Fluorouracil as a Continuous Infusion in Patients with Pancre
... atic Cancer. Cancer Types. Cancer Types. Bone Cancers. Gastrointestinal Cancers. Leukemia. Skin Cancers. Cancer Treatment. Pancreatic Cancer. 13, 1997 of gemcitabine versus 5-FU in mostly stage IV patients, there was a significant survival advantage to utilizing gemcitabine over 5-FU. The dose escalation reached a gemcitabine dose of 1100 mg/m 2 before 2 of 3 had a dose limiting toxicity with the first cycle of ChT septic shock. Conclusions The actuarial survival of 39.5% seems to be much better than the 1-year survival seen in the prior randomized trial of 5-FU 2% versus gemcitabine 18%. OR, perhaps, unresectable locally advanced pancreatic cancer patients should proceed to a phase I and/or II trial with RT + 5-FU followed by gemcitabine + 5-FU. Overall survival not improved with gemcitabine versus fluorouracil plus folinic acid Sep 8, 2010 Overall survival not improved with gemcitabine versus fluorouracil plus folinic acid. nab-Paclitaxel, Gemcitabine Up Survival in Pancreatic Cancer Oct 18, 2013 Improv...
https://oncolink.org/library/article.cfm?c=171&aid=4458&id=526
*  IMRT for Pancreatic cancer | CTCA
IMRT for Pancreatic cancer. Call us 24/7 at 800 615-3055 Chat online now. Chat online with us Please enter your first name. Please enter your last name. Please enter a valid email address so we can respond to your inquiry. Seeking care for. Please enter who you are seeking care for. Type of insurance. PPO Blue Cross HMO Medicare/Medicaid No Insurance Other. Please enter the type of insurance. Please review the disclaimer. Chat now. Other ways to contact us Video chat. Call 800 615-3055 to speak to a cancer information specialist. About Your Cancer How We Treat Cancer Our Difference. Our Hospitals See All Hospitals. Pancreatic cancer Learning. Pancreatic cancer types. Pancreatic cancer symptoms. Pancreatic cancer risk factors. Pancreatic cancer stages. Advanced treatments. Cancer experts. Pancreatic cancer statistics. IMRT for pancreatic cancer What is it Video What is IMRT. With IMRT, our radiation oncologist can adjust the intensity of radiation beams across the treatment area as needed with laser accuracy. ...
http://cancercenter.com/pancreatic-cancer/imrt/
*  Pancreatic cancer support - Pancreatic Cancer Forum - eHealthForum
... Health Forums. Register Forgot your password. Medical Questions. Cancer. Pancreatic Cancer Forum Pancreatic cancer support. Must Read. But what exactly is cancer and how does it affect the body?... Read more. Cancer Causes and Risk Factors What puts you at risk for developing cancer. Learn how you can avoid or reduce exposure to risk factors for cancer here.... Read more. Cancer Symptoms Cancer can occur anywhere in the body. But what are the signs and symptoms of cancer. Learn about general symptoms of cancer here.... Read more. Cancer Pancreatic Cancer Pancreatic Cancer Pancreatic Cancer. Pancreatic Cancer pancreatic tail cancer alternative treatment for pancreatic can... pancreatic cancer specialist on Long Isl... Related Topics Pancreatic fluid high lost a parent to pancreatic cancer. Pancreatic Cyst. My dad found out today, that he has pancreatic cancer. I can travel, and if this mayo clinic is the place that can help him, I can travel.. Did you find this post helpful. You marked this post as helpfu...
http://ehealthforum.com/health/pancreatic-cancer-support-t172851.html
*  Pancreas tumor will cause knee pain -Doctors Lounge(TM)
Pancreas tumor will cause knee pain -Doctors Lounge TM. News. Blogs. Articles. Forums. Twitter. Ask a Doctor. Medical Professional. Author. Volunteer. Medical Reference. Diseases. Symptoms. Labs. Procedures. Drugs. Medical Specialty. Oncology. Surgery. Doctors Lounge - Oncology Answers The information provided on www.doctorslounge.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Back to Oncology Answers List Forum Name: Pancreatic Cancer Question: Pancreas tumor will cause knee pain jandj - Wed Dec 09, 2009 7:43 pm. Share. i have a 6cm tumor in the head of my pancreas. Lately my left knee is giving me alot of pain. Is it related to pancreas. Dr.M.Aroon kamath - Sun Dec 13, 2009 11:49 pm. Share. Hi, At the time of diagnosis of pancreatic cancer, about 50% of all patients have distant disease and about 25% have regional spread The usual sites of metastases in pancreatic cancer are the liver and peritoneal cavity. Skeletal metastases repr...
http://doctorslounge.com/oncology/forums/backup/topic-41562.html
*  .. Category Archives: Pancreatic Cancer .. BRCA Gene Mutations and Risk of Pancreatic Cancer .. Wa
Category Archives: Pancreatic Cancer. BRCA Gene Mutations and Risk of Pancreatic Cancer. By. pancreatica. Published. June 20, 2013. BRCA1 and BRCA2 genes are important in the repair and upkeep of DNA. Mutations in these genes confer a strong tendency to not only more widely known breast cancer, but to other kinds of cancers as well – including contributing to some amount of pancreatic cancer. Now, researchers from the Women’s College Research Institute,. Posted in Pancreatic Cancer. Leave a comment. Watchful Waiting for Small Nonfunctioning Pancreatic Neuroendocrine Tumors. By. pancreatica. Published. June 20, 2013. Neuroendocrine tumors can roughly be divided into functioning and non-functioning categories. The functioning tumors produce an abundance of a given hormone such that the clinical effects of this overabundance can be observed or felt by physicians and/or patients. Non-functioning neuroendocrine tumors produce no hormone, or produce such hormones in sub-clinical quantity, or produce hormones whic...
http://pancreatica.org/category/pancreatic-cancer/page/24/
*  Pancreatic Cancer Diagnosis: Breaking the News - Pancreatic Cancer Center - Everyday Health
... Health A-Z. Cancer. Healthy Recipes. Newsletters. Pancreatic Cancer Pancreatic Cancer Diagnosis: Breaking the News. Deciding when and how to disclose a pancreatic cancer diagnosis is a highly personal decision. Telling family and friends you have cancer is never an easy conversation. When the diagnosis is pancreatic cancer, it can be even harder, given the seriousness of the disease. When Isenberg's father was diagnosed with pancreatic cancer, he asked Isenberg to tell his wife. "My father and I had just learned from his doctor that he did indeed have pancreatic cancer, and was going to die, likely within two years. There is no one right time — or way — to share a pancreatic cancer diagnosis. The decision is very personal and will vary from individual to individual. “Some people wait to tell family and friends until there is a plan in place — that is, when surgery or chemotherapy is scheduled,” says Eileen Coan, MA, MLS, a counselor and medical librarian at The Gathering Place, a nonprofit, community-bas...
http://everydayhealth.com/pancreatic-cancer/pancreatic-cancer-diagnosis-breaking-the-news.aspx
*  Are my Kids at Risk for Colon Cancer? | Oncolink - Cancer Resources
Are my Kids at Risk for Colon Cancer. Oncolink - Cancer Resources. Cancer Types. Cancer Types. Bone Cancers. Brain Tumors. Breast Cancer. Gastrointestinal Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. Pediatric Cancers. Skin Cancers. Testicular Cancer. Urinary Tract Cancers. Cancer Treatment. Getting Treatment. Genetics & Family History. OncoLink University. Cancer Resources. Are my Kids at Risk for Colon Cancer. Are my kids or other family members at risk for colon cancer since I am so young. Answer Liz Prechtel-Dunphy, Oncology Nurse Practitioner at Penn Medicine responds : Being diagnosed with colon cancer at a young age does place your children and siblings at a higher risk of developing colon cancer. It is recommended that they start screening 10 years earlier than when you were diagnosed, for example at age 33. Oral Microflora Tied to Chronic Pancreatitis, Pancreatic Cancer Oct 18, 2011 Salivary microflora potential biomarker for pancreatic cancer, chronic pancreatitis. Pancreatic Cancer and G...
http://oncolink.org/experts/article.cfm?id=3069&ss=134
*  The Effects of Chemotherapy and Radiation Therapy Given Together | Oncolink - Cancer Resources
The Effects of Chemotherapy and Radiation Therapy Given Together. Oncolink - Cancer Resources. Cancer Types. Cancer Types. Bone Cancers. Brain Tumors. Breast Cancer. Endocrine System Cancers. Gastrointestinal Cancers. Gynecologic Cancers. Head and Neck Cancers. Leukemia. Lung Cancers. Lymphomas. OncoLink Vet. Pediatric Cancers. Skin Cancers. Testicular Cancer. Urinary Tract Cancers. Cancer Treatment. Chemotherapy. Radiation. Frequently Asked Questions. Cancer Resources. The Effects of Chemotherapy and Radiation Therapy Given Together OncoLink Last Modified: May 8, 2012. I have many patients that are able to keep working if they were working before, depending on the timing of their radiation treatment. Oral Microflora Tied to Chronic Pancreatitis, Pancreatic Cancer Oct 18, 2011 Salivary microflora potential biomarker for pancreatic cancer, chronic pancreatitis. Pancreatic Cancer and Genetics Pancreatic Enzymes and Suggested Doses When to Take Pancreatic Enzymes Weight loss and Pancreatic Cancer "Warning Signs"...
https://oncolink.org/experts/article.cfm?aid=3979&id=3062&c=125
*  RePub, Erasmus University Repository: Type I interferons in the treatment of pancreati
... c cancer: Mechanisms of action and role of related Receptors. Erasmus Research Institute of Management ERIM. Rotterdam School of Management RSM. Erasmus MC: University Medical Center Rotterdam. Erasmus MC: University Medical Center Rotterdam /. Annals of Surgery /. Type I interferons in the treatment of pancreatic cancer: Mechanisms of action and role of related Receptors Annals of Surgery, Volume 246 - Issue 2 p. OBJECTIVE: We evaluated the role of type I interferons IFNs and IFN receptors in the regulation of cell growth in 3 human pancreatic adenocarcinoma cell lines BxPC-3, MiaPaCa-2, and Panc-1. METHODS: Cell proliferation and apoptosis were evaluated by DNA measurement and DNA fragmentation, respectively. Type I IFN receptor IFNAR-1 and IFNAR-2 subunits was determined by quantitative RT-PCR and immunocytochemistry. The inhibitory effect of IFN-β was stronger than IFN-α in all 3 cell lines and mainly modulated by the stimulation of apoptosis, although cell cycle arrest was induced as well. The expres...
http://repub.eur.nl/pub/35292/
*  MayoClinic.com Health Library - Pancreatic cancer
Find a Doctor. Pancreatic cancer. Pancreatic cancer. Definition Symptoms Causes Risk factors Complications Preparing for your appointment Tests and diagnosis Treatments and drugs Alternative medicine Coping and support Prevention Definition. Pancreatic cancer. Pancreatic cancer. Pancreatic cancer is cancer that forms in the cells of the pancreas. When to see a doctor See your doctor if you experience unexplained weight loss, abdominal pain, jaundice, or other signs and symptoms that bother you. Many diseases and conditions other than cancer may cause similar signs and symptoms, so your doctor may check for these conditions as well as for pancreatic cancer. Most pancreatic cancer begins in the cells that line the ducts of the pancreas. Your doctor may recommend tests and procedures to investigate your signs and symptoms. Imaging tests help your doctor visualize your internal organs, including your pancreas. Staging pancreatic cancer Once a diagnosis of pancreatic cancer is confirmed, your doctor will work to d...
http://riversideonline.com/health_reference/Cancer/DS00357.cfm
*  Quick Facts: A Pancreatic Cancer Infographic - Pancreatic Cancer Research - Lustgarten Foundation
... Cablevision's support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Give Patients Patients Pancreatic Cancer Resources Events Join the Fight Give 100% Goes to Research. Toggle navigation. About Pancreas Cancer Symptoms of PC Types of PC Stages of PC Myths and Facts Pancreatic Cancer Library. About Diagnosis of PC Resources for Patients Resources for Families. Pancreatic cancer research News Research Update Corner Cancer Immunotherapy A Back-Up plan for Pancreatic Cancer. Press Releases News Resources CurePC Campaign. Pancreatic Cancer Research Walks/Runs Event Wrap-Up Create an Event Calendar of Events Community Connections Personalized Web Pages Giving Programs Eyeking Sunglasses London Jewelers Donate Your Vehicle. Resources for Researchers Research Awards Listing Scientific Conferences Lustgarten Sponsored Conferences. Pancreatic Cancer News Press Releases Research Update Corner News Resources. Leave a Legacy Donor Spotlight Giving Progra...
http://lustgarten.org/get-informed/quick-facts-a-pancreatic-cancer-infographic
*  Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer | Cancer Network
Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer. Cancer Network. Cancer Network SearchMedica. Topics: ARS 2015. Breast Cancer. Colorectal Cancer. Lung Cancer. Prostate Cancer. Browse All Topics All Topics ARS 2015 Breast Cancer Colorectal Cancer Leukemia & Lymphoma Lung Cancer Melanoma Prostate Cancer. MAIN MENU Home ONCOLOGY Cancer Management Handbook News Blogs Topics Image IQ Podcasts Conferences. Cancer Network SearchMedica. Topics: ARS 2015. Breast Cancer. Colorectal Cancer. Lung Cancer. Prostate Cancer. Browse All Topics All Topics ARS 2015 Breast Cancer Colorectal Cancer Leukemia & Lymphoma Lung Cancer Melanoma Prostate Cancer. Topics. MAIN MENU Home ONCOLOGY Cancer Management Handbook News Blogs Topics Image IQ Podcasts Conferences. Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer. Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer. NEW ORLEANS-Compared with gemcitabine Gemzar alone, the combination of oxaliplatin Eloxatin and gemcitabine improves both respo...
http://cancernetwork.com/articles/oxaliplatingemcitabine-effective-advanced-pancreatic-cancer
*  Blood Test Might Help Spot Pancreatic Cancer Early - Everyday Health
... Health A-Z. Cancer. Healthy Recipes. Pancreatic Cancer Blood Test Might Help Spot Pancreatic Cancer Early. An earlier pancreatic cancer diagnosis could lead to a possible cure. A new blood test might one day help doctors spot pancreatic cancer in its early stages, Danish scientists report. The researchers said their testing is still too preliminary to be certain it can accurately diagnose pancreatic cancer in patients whose chances of survival are higher. " Pancreatic cancer is a deadly disease. Donald Richards, a pancreatic cancer specialist at Texas Oncology, a U.S. Even with surgery, the majority of patients are not cured, Richards said. For many more patients, the cancer is so far along that surgery is not even an option. "Being able to detect pancreatic cancer at a very early stage could change this, and lead to the cure of this disease," Richards said. When these patterns show up, it raises the likelihood of pancreatic cancer, the researchers said. Nicolai Schultz, from the Herlev Hospital, a part ...
http://everydayhealth.com/news/blood-test-might-help-spot-pancreatic-cancer-early/?xid=aol_eh-news_5_20140120_&aolcat=HLT
*  .. Pancreatic Cancer Risk, Sodas & Juice .. Â .. Welcome to Weekly Health Update .. Books (Click
Pancreatic Cancer Risk, Sodas Juice February 14, 2010 by Robert Wascher Filed under Cancer. Leave a comment. Â. Welcome to Weekly Health Update. “A critical weekly review of important new research findings for health-conscious readers” Â. PANCREATIC CANCER RISK, SODAS JUICE Â. Pancreatic cancer is one of the deadliest of all types of cancer. Â Nearly 45,000 new cases of pancreatic cancer were diagnosed in 2009 in the United States, and more than 35,000 deaths due to this disease occurred during the same year. Â At the time of diagnosis, the vast majority of patients with this terrible disease are already incurable, and overall, 5-year survival rates remain a dismal 5 percent at this time. Â Even among the small minority of patients who are diagnosed with pancreas cancer at a relatively early stage, when the tumor is still confined to the pancreas, the 5-year survival rate is only in the 15 to 20 percent range. The only possible hope for pancreatic cancer cure is very radical surgery, which is often followed b...
http://doctorwascher.com/cancer/pancreatic-cancer-risk-sodas-juice.html
*  Patrons and trustees | Pancreatic Cancer UK
Pancreatic Cancer UK. Login to Pancreatic Cancer UK. Decrease font size Increase font size Reset font size Standard Contrast High Contrast Blue/Black Contrast Cream/Black Contrast. Pancreatic Cancer UK. Join Pancreatic Cancer UK on Facebook Join Pancreatic Cancer UK on Twitter Join Pancreatic Cancer UK on YouTube. Policy and campaigning. Join an event. About the Charity About us and our aims. Breast Cancer Campaign Chief Executive since July 2011, Delyth Morgan previously enjoyed a varied voluntary sector career, which included ten years as Breakthrough Breast Cancer Chief Executive. "I lost my father and a close friend to pancreatic cancer. Like many involved with Pancreatic Cancer UK I feel strongly there is so much more we need to do to fight this terrible disease. I hope that my work experiences and knowledge will contribute to the overall team effort that we all passionately support - striving for long and good lives for all diagnosed with pancreatic cancer.". "The opportunity to be involved, in some sma...
http://pancreaticcancer.org.uk/about-us/about-the-charity/patrons-and-trustees
*  Risk Factors For Pancreas Cancer
... The Sol Goldman Pancreatic Cancer Research Center. Cancer Clinic. Choosing Johns Hopkins. Becoming a Hopkins Patient. Pancreas Cancer Clinic. Pancreas Cyst Clinic. National Familial Pancreas Tumor Registry. Patient Education Pancreas News. Basics of Pancreatic Cancer. The Pancreas. Known Risk Factors. Sol Goldman Center. Patient Education / Basics of Pancreatic Cancer What are risk factors for pancreatic cancer. There are some factors which can increase the risk of acquiring the genetic mutations that may potentially result in pancreatic cancer. Cigarette smoking: Cigarette smoking doubles the risk of pancreatic cancer. Smoking is also associated with early age at diagnosis. Simply put, cigarette smoking is the leading preventable cause of pancreatic cancer. Age: The risk of developing pancreatic cancer increases with age. Race: Studies in the United States have shown that pancreatic cancer is more common in the African American population than it is in the white population. Some of this increased risk m...
http://pathology.jhu.edu/pancreas/BasicRisk.php?area=ba
*  GEN News Highlights Related To | GEN
FDA Nominee Driven by "Data, Data, Data". Analysis of the RNA-Seq and SCA Publication Landscape. The Pons Asinorum of Diagnostic Genomics. FDA Nominee Driven by "Data, Data, Data". Analysis of the RNA-Seq and SCA Publication Landscape. The Pons Asinorum of Diagnostic Genomics. RNA Splicing Factor Linked with Causes of Breast Cancer. GEN News Highlights Related to EC Clears Novartis’ Afinitor for Treating Advanced Pancreatic NET U.K. NICE Rejects Kadcyla, Citing High Cost Merrimack Eyes NDA for MM-398 after Phase III Success FDA Panel Recommends Waiting for Data Before Olaparib Decision Cancer Research UK, CRT Partner with Astellas to Discover Pancreatic Cancer Treatments RedHill Nabs Option to Pick Up RESprotect's Pancreatic Cancer Drug Teaching Bacteria to Tell Cancer Cells to Stop Spreading PDI Acquires RedPath Integrated Pathology Obama Puts a Price on Precision Medicine FDA Commissioner Hamburg Stepping Down Pancreatic Cancer Has Four Genomically Distinct Subtypes Returning Pancreatic Cancer Cells to Norm...
http://genengnews.com/more/related/gen-news-highlights/4/24257/
*  Help Finding Resources During Cancer Treatment | Oncolink - Cancer Resources
Help Finding Resources During Cancer Treatment. Oncolink - Cancer Resources. Tipos de Cancer. Tipos de Cancer. C ncer del Test culo. C nceres de la Piel. C nceres de la V a Urinaria. C nceres del Hueso. C nceres del Pulm n. Tumores del Cerebro. Veterinario de OncoLink. Tratamiento del Cancer. Question If my cancer center doesn't have a social worker, who can help me with financial concerns, insurance problems, co-pay assistance. Answer Christina Bach, Oncology Social Worker at Penn Medicine responds: You can access assistance with coping with financial concerns, insurance problems and co-pay assistance from a variety of resources---here is a list of my go to resources: The American Cancer Society or 800-ACS-2345 general cancer information, financial assistance and supportive services. Cancer Care financial assistance, co-pay assistance, support and education. Cancer Legal Resource Center legal assistance, insurance education, workplace issues. PanCan Pancreatic Cancer specific support, education and resources...
http://es.oncolink.org/experts/article1.cfm?id=3060
*  List clinical trials by disease
... Home. Treatment / Support. Clinical Trials List clinical trials by disease. Share. Clinical Trials. List clinical trials by disease. The results of your search are listed below. To view the details of a trial or study, click on the see details. link. Or start a new search. Searched for: Pancreatic Cancer. 9 results shown below. Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery. See details. Principal Investigator: Gabriela Chiorean Study Number: 8007 Phase: I/II. S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer. See details. Principal Investigator: Gabriela Chiorean Study Number: 9118 Phase: I/II. Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer the Apact Study apact. See details. Principal Investigator: Gabriela Chiorean Study Number: 20140859 Phase: III. Study of Ruxo...
http://fredhutch.org/en/treatment/clinical-trials/list.66.html
*  NCCN Guidelines for Patients® | Pancreatic Cancer
NCCN Guidelines for Patients®. Pancreatic Cancer. NCCN Guidelines for Patients®. Pancreatic Cancer Table of Contents. Table of Contents 7. How to use this book 8. Part 1: About pancreatic cancer 9. Part 1: Contents 10. Part 1: What is the pancreas. 10. Part 1: How does pancreatic cancer start. 11. Part 1: How does pancreatic cancer spread. 12. Part 1: Websites and Review 13. Part 2: Tests for pancreatic cancer 15. Part 2: Contents 16. Part 2: General health tests 16. Part 2: Imaging tests 17. Part 2: Blood tests 20. Part 2: Tissue tests 21. Part 2: Questions about testing to ask your doctor 23. Part 2: Websites and Review 24. Part 3: Overview of cancer treatments 25. Part 3: Contents 26. Part 3: Surgery 26. Part 3: Radiation therapy 28. Part 3: Side effects of treatment 29. Part 3: Chemotherapy 30. Part 3: Targeted therapy 30. Part 3: Clinical trials 32. Part 3: Questions about treatment to ask your doctor 33. Part 3: Questions about clinical trials to ask your doctor 34. Part 3: Websites and Review 35. Part ...
http://nccn.org/patients/guidelines/pancreatic/files/assets/basic-html/toc.html
*  Supportive care of the patient with advanced pancreatic cancer - ResearchGate
... For full functionality of ResearchGate it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser. Article. Supportive care of the patient with advanced pancreatic cancer. Sara Torgerson. Sara Torgerson. Remove suggestion. Lauren A Wiebe. Lauren A Wiebe. Rush University Medical Center. Message author. Remove suggestion. Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Oncology Williston Park, N.Y. Impact Factor: 2.32. 03/2013; 27 3 :183-90. Source: PubMed. ABSTRACT Despite advances in therapy, the average survival rate at 5 years for any patient diagnosed with pancreatic cancer remains only 6%. Throughout the course of cancer, most patients suffer a significant symptom burden and will need numerous interventions targeting these concerns. This paper highlights the most significant problems faced when caring for patients with advanced pancreatic cancer and provides an evidence-based approach to management. In add...
http://researchgate.net/publication/236922080_Supportive_care_of_the_patient_with_advanced_pancreatic_cancer
*  Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer - Full Text View - ClinicalTrials.gov
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of folinic acid, fluorouracil, irinotecan, and oxaliplatin FOLFIRINOX. Primary Outcome Measures: Progression free survival The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Overall survival Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. Rate of resection in patients with locally advanced unresectable disease The rate of surgical resection in the cohort of patients with locally advanced unresectable disease will be determined. metastatic pancreatic cancer locally advanced...
https://clinicaltrials.gov/ct2/show/NCT01523457?recr=Open&cond="Pancreatic Neoplasms"&rank=12
*  Antioxidants linked with lower risk of pancreatic cancer - Vitals
... Antioxidants linked with lower risk of pancreatic cancer. People whose diets include high amounts of vitamins C and E and the mineral selenium may have a lower risk of pancreatic cancer, according to a new study from England. Participants in the study with the highest intake of all three of these compounds were 67 percent less likely to develop pancreatic cancer over a 10-year period compared with the people who had the lowest intakes, according to the study. If a causal link between these compounds and pancreatic cancer was found, the findings suggest that intake of these vitamins and selenium could prevent one in 12 cases of pancreatic cancer, the researchers said. Pancreatic cancer is a deadly disease. The researchers compared the nutrient intakes of the cancer patients with those of 4,000 healthy people. The researchers found that the link between pancreatic cancer and people's intake of selenium and vitamin E showed what's known as a "threshold effect," meaning that it was only the people who had th...
http://vitals.nbcnews.com/_news/2012/07/24/12934025-antioxidants-linked-with-lower-risk-of-pancreatic-cancer
*  : Obesity tied to higher pancreatic cancer risk
... ENN: Environmental News Network -- Know Your Environment. Top Stories Obesity tied to higher pancrea... Our Editorial Affiliate Network. Be a Part of ENN. ABOUT ENN. Contact ENN. From: Reuters Published March 12, 2008 06:59 PM Obesity tied to higher pancreatic cancer risk RELATED ARTICLES Fiber, whole grains may cut pancreatic cancer risk November 23, 2007 12:09 PM. Gum disease may raise cancer risk, study finds May 27, 2008 02:30 PM. Large waist may raise death risk for women April 22, 2008 01:33 PM. NEW YORK Reuters Health - New research suggests that obesity may raise older adults' risk of developing pancreatic cancer, one of the deadliest forms of the disease. The study, by researchers at the U.S. National Cancer Institute, found that men and women who were severely obese were 45 percent more likely than normal-weight adults to develop pancreatic cancer over five years. Abdominal obesity, in particular, was linked to a higher risk of the disease among women, the researchers report in the American Jou...
http://enn.com/top_stories/article/32827
*  Cystic pancreatic neoplasms: Enucleate or resect? - Springer
Cystic pancreatic neoplasms: Enucleate or resect. - Springer. Cystic pancreatic neoplasms: Enucleate or resect. Affiliated with Departments of Surgery and Pathology, Medical College of Wisconsin. Affiliated with Departments of Surgery and Pathology, Medical College of Wisconsin. Affiliated with Departments of Surgery and Pathology, Medical College of Wisconsin. Wilson. Affiliated with Departments of Surgery and Pathology, Medical College of Wisconsin. Pitt. Affiliated with Departments of Surgery and Pathology, Medical College of Wisconsin. Thirty patients with mucinous cystic neoplasms n = 16 , serous cystadenomas n = 10 , and cystic islet cell tumors n = 4 were studied. Enucleation was performed in 11 patients 7 with mucinous cystic neoplasms, 2 with serous cystadenomas and 2 with islet cell tumors , whereas 19 underwent resection of cystic tumors pancreatoduodenectomy in 8 and distal pancreatectomy in 11. About This Journal. Share Share this content on Facebook Share this content on Twitter Share this conte...
http://link.springer.com/article/10.1007/s11605-003-0035-7
*  Pancreatic cancer
{{Infobox disease Name = Pancreatic cancer Image = Diagram showing the position of the pancreas CRUK 356.svg Caption = Diagram showing the position of the pancreas field = Oncology. The most common, 'pancreatic adenocarcinoma', accounts for about 85% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine and loss of appetite. There are usually no symptoms in the disease's early stages, and symptoms that are specific enough to suspect pancreatic cancer typically do not develop until the disease has reached an advanced stage. 2 By the time of diagnosis, pancreatic cancer has often spread to other parts of the body. About 25% of cases are linked to smoking,. The disease is divided into stages, from early stage I to late stage IV. Pancreatic cancer can be treated with surgery, radiotherapy, chemotherapy, palliat...
https://en.wikipedia.org/wiki/Pancreatic_cancer
*  Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer - Full Text View
... - ClinicalTrials.gov. Information provided by Responsible Party : Sofia Perea, Director Clinical Trials Unit., Grupo Hospital de Madrid. Based on this data the investigators designed a phase II clinical trial to evaluate the efficacy of selected treatment for pancreatic cancer patients based on the determination of therapeutic targets. Official Title: Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer. Experimental: Tarteted Therapy Drug: Targeted Therapy Tailored Treatment Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen Tim Synthase TS neg , ERCC-1 neg , Topoisomerase I Topo I pos : FOLFIRINOX TS neg , ERCC-1 neg , Topo I neg : FOLFOX TS neg , ERCC-1 pos , Topo I pos : FOLFIRI TS neg , ERCC-1 pos , Topo I neg : Capecitabine/Gemcitabine TS pos , EGFR Not Amplificate, K-Ras Mutation pos : Gemcitabine single agent TS pos , EGFR Ampl or K-Ras mut neg : Gemcitabine plus Erlotinib. Active Compa...
https://clinicaltrials.gov/ct2/show/NCT01394120
*  Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherap
Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer. Cancer Types. Cancer Types. Bone Cancers. Gastrointestinal Cancers. Leukemia. Lung Cancers. Metastatic Cancer. Skin Cancers. Cancer Treatment. This phase III trial was designed to compare initial chemoradiotherapy with a 5FU based regimen followed by gemcitabine monotherapy to gemcitabine monotherapy alone in patients with locally advanced, non-metastatic, pancreatic cancer. Patients were randomized 1:1 to receive concurrent chemoradiotherapy CHRT versus gemcitabine GEM alone. Median survival was 8.6 months in the CHRT arm versus 13 months in the GEM arm p = 0.057. One year OS was 32% versus 53% p = 0.05 in the CHRT arm versus GEM and 1 year PFS was 14% versus 32% p = 0.09, respectively. Clinical/Scientific Implications This study represents a comparison of concurrent chemoradiotherapy to gemcitabine monotherapy in patients with locally advanced pancreatic carcinoma. The authors did not find benefit to use of the described c...
http://oncolink.org/conferences/article1.cfm?id=1696
*  Stage 4 pancreatic cancer, what's the point in chemo? - Pancreatic Cancer Forum - Cancer Forums
Stage 4 pancreatic cancer, what's the point in chemo. - Pancreatic Cancer Forum - Cancer Forums. A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members. Forum. New Posts. Forum Actions. Mark Forums Read. Today's Posts. View Site Leaders. Forum. Specific Cancers. Pancreatic Cancer Forum. Stage 4 pancreatic cancer, what's the point in chemo. To start viewing messages, select the forum that you want to visit from the selection below. Thread: Stage 4 pancreatic cancer, what's the point in chemo. View Profile. View Forum Posts. View Blog Entries. Regular User. Join Date Feb 2012 Posts 24. Stage 4 pancreatic cancer, what's the point in chemo. Reply With Quote. Hope2012. View Profile. View Forum Posts. View Blog Entries. Top User. Join Date Nov 2011 Location Canada Posts 874. A person doesn't know just how long they will go on with chemo...could be months, could be years for some. Dad diagnosed with Stage IV PC with mets to liver March 4, 20...
http://cancerforums.net/threads/22238-Stage-4-pancreatic-cancer-what-s-the-point-in-chemo
*  A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic cancer | Onco
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic cancer. Cancer Types. Cancer Types. Bone Cancers. Head and Neck Cancers. Lung Cancers. Pediatric Cancers. Skin Cancers. Cancer Treatment. Methods The study intended to randomize patients into one of 4 groups following surgical resection: A Observation, B chemoradiotherapy, C chemotherapy, or D chemoradiotherapy followed by maintenance chemotherapy. The Chemoradiotherapy category consisted of groups B D; the No Chemoradiotherapy category consisted of groups A C; the Chemotherapy category consisted of groups C D; and the No Chemotherapy category consisted of groups A D. The time to recurrence and 1 year disease-free survival for chemoradiotherapy vs no chemoradiotherapy was 10.7 months and 46% vs 15.2 months and 58%, respectively. When comparing chemotherapy vs no chemotherapy, the time to recurrence and 1 year disease-free survival was 15.3 months and 58% vs 9.4 months and 43%, respectively. Safety of Clinical Trials Thyroid...
http://oncolink.org/library/article.cfm?c=2&s=41&id=787
*  Watch Our Experts Discuss the Latest Techniques and Research in Pancreatic Cancer | Memorial Sloan K
Watch Our Experts Discuss the Latest Techniques and Research in Pancreatic Cancer. Memorial Sloan Kettering Cancer Center. Find a Doctor. Watch Our Experts Discuss the Latest Techniques and Research in Pancreatic Cancer. Medical experts from Memorial Sloan Kettering discuss the diagnosis and treatment of pancreatic cancer and current research initiatives. Most patients, says Dr. Surgery is only appropriate in about 25 to 30 percent of pancreatic cancer cases; in every case, our multidisciplinary team will collaborate to decide what combination of radiation, chemotherapy, and/or surgery will work for the patient, and in what order. Patients with earlier-stage cancers generally do better with surgery and chemotherapy, which is the most effective treatment combination we have for the disease, says Dr. Memorial Sloan Kettering experts are also leading a number of clinical trials for pancreatic cancer treatments. Pancreatic Cancer. Multiple IPMN tumors have returned to my pancreas, and I will need to consult at Me...
https://mskcc.org/blog/watch-experts-discuss-latest-techniques-and-research-pancreatic?glossary=on
*  Trying to raise the profile of pancreatic cancer, deadly yet lagging in research funding - philly-ar
... chives. Breast Cancer. Pancreatic Cancer. Surgeon Charles Yeo and a pancreatic cancer patient, Annerose Langan, her husband, Peter, and daughter Trish. Yeo had performed surgery on Langan in December, using a procedure that prolongs survival. "It's an annual pilgrimage," said Yeo, chief of surgery at Jefferson and the area's leading practitioner of the Whipple procedure, the surgery that gives many patients the best chance of surviving the deadly disease. Even with advances in surgical techniques, diagnosis, and drugs, he estimates that a patient operated on for stage two pancreatic cancer, where the disease has not spread to other body parts, may now have a five-year survival rate of 25 to 40 percent. This is far better than the overall survivor rate of just 6 percent, which includes the majority of pancreatic cancers that are inoperable. Pancreatic cancer is now the fourth-leading cause of cancer deaths in the United States behind lung, breast, and colorectal cancers. 2 by 2020, with annual deaths doubl...
http://articles.philly.com/2013-01-29/entertainment/36598414_1_pancreatic-cancer-survival-rates-cancer-deaths
*  A Simple Blood Test May Catch Early Pancreatic Cancer
Experts. Johns Hopkins Medicine. “While far from perfect, we think we have found an early detection marker for pancreatic cancer that may allow us to locate and attack the disease at a much earlier stage than we usually do.” For their study, Ahuja and her colleagues were able to identify two genes, BNC1 and ADAMTS1, which together were detectable in 81 percent of blood samples from 42 people with early-stage pancreatic cancer, but not in patients without the disease or in patients with a history of pancreatitis, a risk factor for pancreatic cancer. Specifically, researchers say, they found BNC1 and ADAMTS1 in 97 percent of tissues from early-stage invasive pancreatic cancers. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. Permalink to this article Related Experts GW Experts Available to Comment on Stories for Breast Cancer Awareness Month October is Breast Cance...
http://newswise.com/articles/view/609342/?sc=rsmn
*  Pancreatic Cancer Case-Control Consortium
... Search. . HOME. ABOUT US. History of PanC4. Members & Institutional Affiliations. Authorship Policy. Publications. Steering Committee. RESEARCH. PANC4 MEMBERS. CONTACT US. Steering Committee. Contact Information. ABOUT US. Published Articles By PanC4 Members. Featured PanC4 Article. Bosetti C, Rosato V, Li D, et al. Diabetes, antidiabetic medications and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. Ann Oncol. 2014 Jul 23. Article Link Abstract from Bosetti et al Article BACKGROUND: Type 2 diabetes mellitus has been associated with an excess risk of pancreatic cancer, but the magnitude of the risk and the time-risk relationship are unclear, and there is limited information on the role of antidiabetic medications. PATIENTS AND METHODS: We analyzed individual-level data from 15 case-control studies within the Pancreatic Cancer Case-Control Consortium, including 8305 cases and 13,987 controls. Pooled odds ratios ORs were estimated from ...
http://panc4.org/about_publication.html
*  JAMA Network | JAMA | Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer
Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer. Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer FREE Dominique S. Article. We therefore examined the relationship between body mass index BMI, height, and physical activity and the risk of pancreatic cancer in 2 large prospective cohort studies of men and women. Similarly, women in the NHS reported their baseline height and current weight in 1976. In multivariable analyses, an increment of 1 BMI unit 1 kg/m 2 was associated with a 5% increased risk of pancreatic cancer in the HPFS RR, 1.05; 95% CI, 1.00-1.11 and a 3% increased risk in the NHS RR, 1.03; 95% CI, 1.00-1.07. Relative Risk RR for Pancreatic Cancer by Height and Body Mass Index BMI in the NHS and HPFS*. After adjusting for current BMI and other risk factors, the risk of pancreatic cancer associated with BMI at age 18 years was attenuated multivariable RR, 1.09; 95% CI, 0.66-1.80. We observed an association between height and risk of pancreatic cancer in bot...
http://jama.jamanetwork.com/article.aspx?articleid=194126
*  Treatment of Pancreatic Cancer | Touch Oncology | Independent Insight for Medical Specialists
Treatment of Pancreatic Cancer. Search Site Search Search. Aims Scope and Instructions for Authors European Oncology Haematology Oncology Hematology Review US Editorial Board Articles Media Gallery Media Partners Press Releases. Breakthrough and Cancer Pain Palliative Oncology Cancer Cachexia Chemotherapy Induced Nausea, Vomiting and Neutropenia Chemotherapy-induced Neutropenia Oral Mucositis. Media Partners. All Media Partners. Treatment of Pancreatic Cancer. In 2004, approximately 31,860 new cases will be diagnosed, and 31,270 of affected patients are expected to die from their disease.1 Patients usually present with advanced disease, and two-thirds of them either have locally advanced or metastatic disease. Based on CT scan findings with help from endoscopic ultrasound if needed, patients can be categorized as those with potentially resectable cancer, borderline resectable cancer, unresectable locally advanced cancer, and metastatic pancreatic cancer. Resectable and Borderline Resectable Pancreatic Cancer ...
http://touchoncology.com/articles/treatment-pancreatic-cancer
*  2 Drugs Look Promising for Rare Pancreatic Cancer
... Symptoms. Cancer. WebMD Pain Coach Track your pain levels, triggers, and treatments. Get Started WebMD My Medicine Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more. Living Healthy. Living Healthy Centers View All. Family Pregnancy. Family and Pregnancy Centers Pregnancy. Featured Topics Know the Signs of Early Pregnancy. News Experts. WebMD Health Experts and Community. WebMD Communities Connect with people like you, and get expert guidance on living a healthy life. Get Answers WebMD Newsletters Sign up to receive WebMD's award-winning content delivered to your inbox. 2 Drugs Look Promising for Rare Pancreatic Cancer Targeted Treatment Slowed Disease Progression in Studies WebMD News Archive. The Sutent/Afinitor Studies The Sutent phase III study was originally designed to include about 340 patients with advanced pancreatic neuroendocrine tumors taking either the drug or placebo. Yao says canker sores were the most commonly reported side effect in the Afinit...
http://webmd.com/cancer/pancreatic-cancer/news/20110208/2-drugs-look-promising-for-rare-pancreatic-cancer?page=2
*  Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer - No
... Study Results Posted - ClinicalTrials.gov. Skip to Main Content. A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies:. Advanced Search. Help. Studies by Topic. Glossary. Find Studies. Basic Search. Advanced Search. See Studies by Topic. See Studies on Map. How to Search. How to Use Search Results. How to Find Results of Studies. How to Read a Study Record. About Clinical Studies. Learn About Clinical Studies. Other Sites About Clinical Studies. Glossary of Common Site Terms. Submit Studies. Why Should I Register and Submit Results. FDAAA 801 Requirements. How to Apply for an Account. How to Register Your Study. How to Edit Your Study Record. How to Submit Your Results. Frequently Asked Questions. Support Materials. Training Materials. Resources. Selected Publications. Clinical Alerts and Advisories. RSS Feeds. Trends, Charts, and Maps. Downloading Content for Analysis. About This Site. ClinicalTrials.gov Background. About the Results Database. ...
https://clinicaltrials.gov/ct2/show/results/NCT01836432?view=record
*  Awards Listing - 2009 - Pancreatic Cancer Research - Lustgarten Foundation
... Cablevision's support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research. Give Patients Patients Pancreatic Cancer Resources Events Join the Fight Give 100% Goes to Research. Pancreatic Cancer Research Walks/Runs Event Wrap-Up Create an Event Calendar of Events Community Connections Personalized Web Pages Giving Programs Eyeking Sunglasses London Jewelers Donate Your Vehicle. Resources for Researchers Research Awards Listing Scientific Conferences Lustgarten Sponsored Conferences. Major Research Initiatives Early Detection Initiatives Pancreatic Cancer Research Consortium Pancreatic Cancer Genome Project. Leave a Legacy Donor Spotlight Giving Programs EyeKing Sunglasses Champions for Charity London Jewelers Donate Your Vehicle. How Your Money is Spent Make a Secure Online Donation Mail a Donation Support the curePC Campaign Purchase a Purple Bracelet Volunteer Community Connections. Research follows dollars, and The Lustgarten Foundation believes ...
http://lustgarten.org/AwardsListing2009
*  First Test to Monitor Pancreatic Cancer Receives FDA Clearance | Cancer Network
First Test to Monitor Pancreatic Cancer Receives FDA Clearance. Cancer Network. Cancer Network SearchMedica. Topics: ARS 2015. Colorectal Cancer. Browse All Topics All Topics ARS 2015 Breast Cancer Colorectal Cancer Leukemia & Lymphoma Lung Cancer Melanoma Prostate Cancer. MAIN MENU Home ONCOLOGY Cancer Management Handbook News Blogs Topics Image IQ Podcasts Conferences. Cancer Network SearchMedica. Topics: ARS 2015. Colorectal Cancer. Browse All Topics All Topics ARS 2015 Breast Cancer Colorectal Cancer Leukemia & Lymphoma Lung Cancer Melanoma Prostate Cancer. Topics. MAIN MENU Home ONCOLOGY Cancer Management Handbook News Blogs Topics Image IQ Podcasts Conferences. First Test to Monitor Pancreatic Cancer Receives FDA Clearance. First Test to Monitor Pancreatic Cancer Receives FDA Clearance. The availability of the CA 19-9 test in the United States will give us a new tool for early assessment of the effectiveness of the many new drugs that are becoming available for the treatment of metastatic cancer of the ...
http://cancernetwork.com/articles/first-test-monitor-pancreatic-cancer-receives-fda-clearance
*  .. Monthly Archives: April 2013 .. MicroRNAs as markers for IPMNs .. Recent Posts .. Categories ..
Monthly Archives: April 2013. newer articles →. MicroRNAs as markers for IPMNs. By. pancreatica. Published. April 17, 2013. Intraductal papillary mucinous neoplasms IPMNs are not fully understood, but are felt by many to be precursor tumors to full blown pancreatic cancer adenocarcinoma. Thus, an interesting study was recently published by Italian researchers including Giovannetti and colleagues from the University of Pisa in the Annals of Oncology the official journal of the European Society for Medical. Posted in Medical Research, Pancreatic Cancer. Tagged Medical Research, Pancreatic Cancer. Leave a comment. newer articles →. Recent Posts. Pancreatic Cancer Work-up That Includes a Fine Needle Biopsy placed via endoscope locating ultra-sound Appears to Offer no Additional Risk. Cell Surface Heparan Sulfate Proteoglycan Found on Extracellular Vesicles in Serum May Aid in the Earlier Diagnosis of Cancer of the Pancreas. Locally Advanced Pancreatic Cancer: Induction Chemo with Whipple + Vascular Targets. Cat...
http://pancreatica.org/2013/04/page/2/
*  Tests for pancreatic cancer | Cancer Research UK
Tests for pancreatic cancer. Pancreatic cancer About pancreatic cancer The pancreas Causes Screening Symptoms Types Seeing a specialist What to ask Diagnosing pancreatic cancer Tests Biopsy Further tests What to ask Treating pancreatic cancer Stages Outlook and stats Treatment types Surgery Types of surgery Removing the cancer Relieving symptoms Having surgery What to ask Chemotherapy Radiotherapy Advanced cancer What it is Drugs Radiotherapy Stents Pain control What to ask Follow up Research What to ask Living with pancreatic cancer Coping Diet Advanced cancer What to ask About this section Organisations Reading list Pancreatic cancer clinical trials Pancreatic cancer questions and answers. Tests for pancreatic cancer This page has information about the tests and appointments you may have if your doctor thinks you may have cancer of the pancreas. A quick guide to what's on this page Going to the GP At the hospital Blood tests Ultrasound scan CT Scan. Endoscopic ultrasound MRI scan ERCP test Type of MRI scan ...
http://cancerresearchuk.org/about-cancer/type/pancreatic-cancer/diagnosis/tests-for-pancreatic-cancer
*  New markers shed light on pancreatic cancer - For Medical Professionals - Mayo Clinic
... For Medical Professionals Clinical updates. New markers shed light on pancreatic cancer. PGS technology One area of investigation involves the use of polarization gating spectroscopy PGS technology to detect early pancreatic adenocarcinoma by measuring markers of increased blood supply, such as deoxyhemoglobin concentration and blood vessel radius, in the adjacent duodenal mucosa. To evaluate the feasibility, safety and efficacy of PGS measurements in the duodenum to determine markers of early increased blood supply, Mayo Clinic researchers, in partnership with biomedical engineers at Northwestern University, conducted a prospective pilot study comparing patients with pancreatic adenocarcinoma with healthy controls. Results showed that deoxyhemoglobin concentration and blood vessel radius measured from the ampulla had the greatest ability to differentiate cancer patients from controls. Deoxyhemoglobin measurements alone achieved sensitivity of 92 percent and specificity of 86 percent in distinguishing be...
http://mayoclinic.org/medical-professionals/clinical-updates/digestive-diseases/new-markers-shed-light-on-pancreatic-cancer?p=1
*  JAMA Network | JAMA Surgery | Omega-3 Fatty Acids: Investigations From Cytokine Regulation to
CME. Previous Article Next Article. Special Article. Article. References. ANTI-INFLAMMATORY PROPERTIES OF Ω-3 FAS THROUGH TNF. ANTIANGIOGENIC PROPERTIES OF Ω-3 FAS. MECHANISMS OF Ω-3 FA CYTOKINE REGULATIONS. DIRECT SIGNAL TRANSDUCTION EFFECT OF Ω-3 FAS ON NF-ΚB. Ω-3 FAS AND CANCER. ROLE OF Ω-3 FAS IN PANCREATIC CANCER. CAN Ω-3 FA CONTROL PANCREATIC CANCER RESISTANCE TO GEMCITABINE THROUGH NF-ΚB. GENETIC EXPRESSION PROFILING OF Ω-3 FA TREATMENT ON PANCREATIC CANCER. ARTICLE INFORMATION. REFERENCES. ANTI-INFLAMMATORY PROPERTIES OF Ω-3 FAS THROUGH TNF ABSTRACT. ANTI-INFLAMMATORY PROPERTIES OF Ω-3 FAS THROUGH TNF. ANTIANGIOGENIC PROPERTIES OF Ω-3 FAS. MECHANISMS OF Ω-3 FA CYTOKINE REGULATIONS. DIRECT SIGNAL TRANSDUCTION EFFECT OF Ω-3 FAS ON NF-ΚB. Ω-3 FAS AND CANCER. ROLE OF Ω-3 FAS IN PANCREATIC CANCER. CAN Ω-3 FA CONTROL PANCREATIC CANCER RESISTANCE TO GEMCITABINE THROUGH NF-ΚB. GENETIC EXPRESSION PROFILING OF Ω-3 FA TREATMENT ON PANCREATIC CANCER. ARTICLE INFORMATION. These data support the contention that ant...
http://archsurg.jamanetwork.com/article.aspx?articleid=406049
*  Potential target antigens for immunotherapy in human pancreatic cancer.
... MedLine Citation:. BACKGROUND: To be effective and selective, immunotherapy ideally targets specifically tumor cells and spares normal tissues. Still very little is known about the expression of tumor-related antigens in pancreatic neoplasms. Cancer Testis antigens CT are antigens shared by a variety of malignant tumors, but not by normal tissues with the exception of germ cells in testis. Restricted expression in neoplastic tissues and inherent immunogenic features make CT antigens ideal for use in immunotherapy. In addition we analyzed the expression of HERV-K-MEL, an immunogenic antigen of viral origin. Tumor-associated antigen expression of MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, LAGE-1, NY-ESO-1, SCP-1, SSX-2, SSX-4 and HERV-K-MEL was assessed by PCR. Sequencing of PCR products were performed to assess the expression of SSX-4 in neoplastic and normal pancreatic tissues. RESULTS: Three of 10 tested antigens were expressed in over 10% of malignant pancreatic tissue samples. SSX-4 was found positive in 30...
http://biomedsearch.com/nih/Potential-target-antigens-immunotherapy-in/17320278.html

PancreatoblastomaCystic, mucinous, and serous neoplasms: Cystic, mucinous, and serous neoplasms is a group of tumors.Kidney tumour: Kidney tumours (or kidney tumors), also known as renal tumours, are tumours, or growths, on or in the kidney. These growths can be benign or malignant (cancerous).Intraductal papillary mucinous neoplasmThyroid cancerMyelodysplastic–myeloproliferative diseases: Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies disorders created by the World Health Organization which have characteristics of both myelodysplastic and myeloproliferative conditions.Targeted therapy of lung cancer: Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.Sialoblastoma: A sialoblastoma is a low-grade salivary gland neoplasm that recapitulates primitive salivary gland anlage. It has previously been referred to as congenital basal cell adenoma, embryoma, or basaloid adenocarcinoma.Solution precursor plasma spray: Solution Precursor Plasma Spray (SPPS) is a thermal spray process where a feedstock solution is heated and then deposited onto a substrate. Basic properties of the process are fundamentally similar to other plasma spraying processes.Goblet cell carcinoid: The goblet cell carcinoid, abbreviated GCC and also known as crypt cell carcinoma and neuroendocrine tumour with goblet cell differentiation, is a rare biphasic gastrointestinal tract tumour that consists of a neuroendocrine component and a conventional carcinoma, histologically arising from Paneth cells.Metastatic liver disease: A liver metastasis is a malignant tumor in the liver that has spread from another organ affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein).Pancreatic mucinous cystic neoplasm: Pancreatic mucinous cystic neoplasm, also mucinous cystic neoplasm of the pancreas and mucinous cystic tumour, is a grouping of cystic neoplasms that arise from the pancreas. They may be benign, malignant or in between.Ovarian Cancer National Alliance: The Ovarian Cancer National Alliance is an advocacy organization for women with ovarian cancer in the United States. To advance the interests of women with ovarian cancer, the organization advocates at a national level for increases in research funding for the development of an early detection test, improved health care practices, and life-saving treatment protocols.Ductal carcinoma: Ductal carcinoma is a type of tumor that primarily presents in the ducts of a gland.Vascular tissue neoplasmIntraocular lymphoma: Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye secondarily from a metastasis from a non-ocular tumor or may arise within the eye primarily (primary intraocular lymphoma, PIOL).Polymorphous low-grade adenocarcinoma: Polymorphous low-grade adenocarcinoma, often abbreviated PLGA, is a rare, asymptomatic, slow-growing malignant salivary gland tumor. It is most commonly found in the palate.Spaceflight radiation carcinogenesisAggressive digital papillary adenocarcinoma: Aggressive digital papillary adenocarcinoma (also known as a digital papillary adenocarcinoma and papillary adenoma) is a cutaneous condition characterized by an aggressive malignancy involving the digit between the nailbed and the distal interphalangeal joint spaces.Bob ChampionInflammatory myofibroblastic tumourGlandular and epithelial neoplasm: Glandular and epithelial neoplasm is a grouping of tumors arising from the glands and epithelium.Mucinous cystadenocarcinoma of the lung: Mucinous cystadenocarcinoma of the lung (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled growth of transformed epithelial cells originating in lung tissue.Thyroid adenomaOsteolipochondroma: Osteolipochondroma (osteo, bone, lipos, fat, + chondros, cartilage, oma, tumor) is a cartilaginous tumor containing fatty and bony tissue.Hematological Cancer Research Investment and Education Act: The Hematological Cancer Research Investment and Education Act of 2001 (P.L.Adnexal and skin appendage neoplasms: Adnexal and skin appendage neoplasms is a group of tumors.ABCD rating: ABCD rating, also called the Jewett staging system or the Whitmore-Jewett staging system, is a staging system for prostate cancer that uses the letters A, B, C, and D.Hidradenocarcinoma: Hidradenocarcinoma (also known as malignant hidradenoma, malignant acrospiroma, clear cell eccrine carcinoma, or primary mucoepidermoid cutaneous carcinoma) is a malignant adnexal tumor of the sweat gland. It is the malignant variant of the benign hidradenoma.World Lymphoma Awareness Day: World Lymphoma Awareness Day (WLAD) is held on September 15 every year and is a day dedicated to raising awareness of lymphoma, an increasingly common form of cancer. It is a global initiative hosted by the Lymphoma Coalition (LC), a non-profit network organisation of 63 lymphoma patient groups from 44 countries around the world.Bone tumorCancer/testis antigen family 45, member a5Papillary serous cystadenocarcinomaLittoral cell angioma: Littoral cell angioma, abbreviated LCA, and formally known as littoral cell angioma of the spleen, is a benign tumour of the spleen that arises from the cells that line the red pulp.Ovarian serous cystadenoma: Ovarian serous cystadenoma, also (less precisely) known as serous cystadenoma, is a very common benign ovarian tumour.Oncotype DX Colon Cancer AssayCancer biomarkers: A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer.Old German Shepherd Dog: Old German Shepherd Dog () is a controversial predicate for the long-hair variation of the German Shepherd Dog (), which is not a separate breed recognized by the Fédération Cynologique Internationale. Nonetheless, there are efforts to establish this variety as a separate breed.Germ cell tumorAdipose tissue neoplasm: An adipose tissue neoplasm is a neoplasm derived from adipose tissue.PanitumumabDuodenal cancerPrimary mediastinal B-cell lymphoma: Primary mediastinal B-cell lymphoma, abbreviated PMBL, is a type of lymphoma that rises in the mediastinum and predominantly affects young adults.GlossectomyAutoschizis: "Autoschizis" is a term derived from the Greek αὐτο- auto-, meaning "self", and σχίζειν skhizein, "to split". It was introduced in 1998 to describe a novel form of cancer cell death characterized by a reduction in cell size that occurs due to the loss of cytoplasm through self-excision (the cell splits open) without the loss of cell organelles, morphologic degradation of the cells nucleus and nucleolus without the formation of apoptotic bodies and destruction of the cell membrane.Acinar cell carcinoma of the pancreas: Acinar cell carcinoma of the pancreas, also acinar cell carcinoma, is a rare malignant exocrine tumour of the pancreas. It represents 5% of all exocrine tumours of the pancreas, making it the second most common type of pancreatic cancer.Spinal tumorVaginal intraepithelial neoplasiaOncocytomaEpidemiology of cancer: The epidemiology of cancer is the study of the factors affecting cancer, as a way to infer possible trends and causes. The study of cancer epidemiology uses epidemiological methods to find the cause of cancer and to identify and develop improved treatments.Janus kinase 2: Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.HemangiosarcomaAnaplastic carcinoma: Anaplastic carcinoma is a general term for a malignant neoplasm arising from the uncontrolled proliferation of transformed cells of epithelial origin, or showing some epithelial characteristics, but that reveal no cytological or architectural features of associated with more differentiated tumors, such as the glandular formation or special cellular junctions that typical of adenocarcinoma and squamous cell carcinoma, respectively.Adenocarcinoma of the lung: Adenocarcinoma of the lung (pulmonary adenocarcinoma) is a common histological form of lung cancer that contains certain distinct malignant tissue architectural, cytological, or molecular features, including gland and/or duct formation and/or production of significant amounts of mucus.PancreatectomyLudwig G. KempeBreast cancer classification: Breast cancer classification divides breast cancer into categories according to different schemes, each based on different criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes.Dense artery sign: In medicine, the dense artery sign or hyperdense artery sign is a radiologic sign seen on computer tomography (CT) scans suggestive of early ischemic stroke. In earlier studies of medical imaging in patients with strokes, it was the earliest sign of ischemic stroke in a significant minority of cases.Orbital lymphoma: Orbital lymphoma is a common type of non-Hodgkin lymphoma that occurs near or on the eye. Common symptoms include decreased vision and uveitis.

(1/40131) Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis.

The cyclin-dependent kinase inhibitor p21waf1/Cip1 is a downstream effector of the p53-dependent cell growth arrest. We report herein that p21 was cleaved by caspase-3/CPP32 at the site of DHVD112L during the DNA damage-induced apoptosis of cancer cells. The cleaved p21 fragment could no more arrest the cells in G1 phase nor suppress the cells undergoing apoptosis because it failed to bind to the proliferating cell nuclear antigen (PCNA) and lost its capability to localize in the nucleus. Thus, caspase-3-mediated cleavage and inactivation of p21 protein may convert cancer cells from growth arrest to undergoing apoptosis, leading to the acceleration of chemotherapy-induced apoptotic process in cancer cells.  (+info)

(2/40131) Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men.

BACKGROUND: Depressed respiratory function and respiratory symptoms are associated with impaired survival. The present study was undertaken to assess the relation between respiratory symptoms and mortality from cardiovascular causes, cancer and all causes in a large population of middle-aged men. METHODS: Prospective population study of 6442 men aged 51-59 at baseline, free of clinical angina pectoris and prior myocardial infarction. RESULTS: During 16 years there were 1804 deaths (786 from cardiovascular disease, 608 from cancer, 103 from pulmonary disease and 307 from any other cause). Men with effort-related breathlessness had increased risk of dying from all of the examined diseases. After adjustment for age, smoking habit and other risk factors, the relative risk (RR) associated with breathlessness of dying from coronary disease was 1.43 (95% CI : 1.16-1.77), from stroke 1.77 (95% CI: 1.07-2.93), from any cardiovascular disease 1.48 (95% CI : 1.24-1.76), cancer 1.36 (95% CI : 1.11-1.67) and from any cause 1.62 (95% CI: 1.44-1.81). An independent effect of breathlessness on cardiovascular death, cancer death and mortality from all causes was found in life-time non-smokers, and also if men with chest pain not considered to be angina were excluded. An independent effect was also found if all deaths during the first half of the follow-up were excluded. Men with cough and phlegm, without breathlessness, also had an elevated risk of dying from cardiovascular disease and cancer, but after adjustment for smoking and other risk factors this was no longer significant. However, a slightly elevated independent risk of dying from any cause was found (RR = 1.18 [95% CI: 1.02-1.36]). CONCLUSION: A positive response to a simple question about effort related breathlessness predicted subsequent mortality from several causes during a follow-up period of 16 years, independently of smoking and other risk factors.  (+info)

(3/40131) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of 5-fluorouracil (5-FU) catabolism. We report lymphocytic DPD data concerning a group of 53 patients (23 men, 30 women, mean age 58, range 36-73), treated by 5-FU-based chemotherapy in different French institutions and who developed unanticipated 5-FU-related toxicity. Lymphocyte samples (standard collection procedure) were sent to us for DPD determination (biochemical method). Among the whole group of 53 patients, 19 had a significant DPD deficiency (DD; below 150 fmol min(-1) mg(-1) protein, i.e. less than 70% of the mean value observed from previous population study). There was a greater majority of women in the DD group (15 out of 19, 79%) compared with the remaining 34 patients (15 out of 34, 44%, P<0.014). Toxicity was often severe, leading to patient death in two cases (both women). The toxicity score (sum of WHO grading, theoretical range 0-20) was twice as high in patients with marked DD (below 100 pmol min(-1) mg(-1) protein, n = 11, mean score = 13.2) compared with patients with moderate DD (between 150 and 100 pmol min(-1) mg(-1) protein, n = 8, mean score = 6.8), P = 0.008. In the DD group, there was a high frequency of neurotoxic syndromes (7 out of 19, 37%). The two deceased patients both had severe neurotoxicity. The occurrence of cardiac toxicity was relatively rare (1 out of 19, 5%). These data suggest that women are particularly prone to DPD deficiency and allow a more precise definition of the DD toxicity profile.  (+info)

(4/40131) Cancer incidence in the south Asian population of England (1990-92).

Cancer incidence among English south Asians (residents in England with ethnic origins in India, Pakistan or Bangladesh) is described and compared with non-south Asian and Indian subcontinent rates. The setting for the study was areas covered by Thames, Trent, West Midlands and Yorkshire cancer registries. The study identified 356 555 cases of incident cancer (ICD9:140-208) registered between 1990 and 1992, including 3845 classified as English south Asian. The main outcome measures were age specific and directly standardized incidence rates for all cancer sites (ICD9:140-208). English south Asian incidence rates for all sites combined were significantly lower than non-south Asian rates but higher than Indian subcontinent rates. English south Asian rates were substantially higher than Indian subcontinent rates for a number of common sites including lung cancer in males, breast cancer in females and lymphoma in both sexes. English south Asian rates for childhood and early adult cancer (0-29 years) were similar or higher than non-south Asian rates. English south Asian rates were significantly higher than non-south Asian rates for Hodgkin's disease in males, cancer of the tongue, mouth, oesophagus, thyroid gland and myeloid leukaemia in females, and cancer of the hypopharynx, liver and gall bladder in both sexes. The results are consistent with a transition from the lower cancer risk of the country of ethnic origin to that of the country of residence. They suggest that detrimental changes in lifestyle and other exposures have occurred in the migrant south Asian population.  (+info)

(5/40131) Cancer mortality by educational level in the city of Barcelona.

The objective of this study was to examine the relationship between educational level and mortality from cancer in the city of Barcelona. The data were derived from a record linkage between the Barcelona Mortality Registry and the Municipal Census. The relative risks (RR) of death and 95% confidence intervals (CIs) according to level of education were derived from Poisson regression models. For all malignancies, men in the lowest educational level had a RR of death of 1.21 (95% CI 1.13-1.29) compared with men with a university degree, whereas for women a significant decreasing in risk was observed (RR 0.81; 95% CI 0.74-0.90). Among men, significant negative trends of increasing risk according to level of education were present for cancer of the mouth and pharynx (RR 1.70 for lowest vs. highest level of education), oesophagus (RR 2.14), stomach (RR 1.99), larynx (RR 2.56) and lung (RR 1.35). Among women, cervical cancer was negatively related to education (RR 2.62), whereas a positive trend was present for cancers of the colon (RR 0.76), pancreas (RR 0.59), lung (RR 0.55) and breast (RR 0.65). The present study confirms for the first time, at an individual level, the existence of socioeconomic differences in mortality for several cancer sites in Barcelona, Spain. There is a need to implement health programmes and public health policies to reduce these inequities.  (+info)

(6/40131) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.

p27kip1 (p27) is a member of the universal cyclin-dependent kinase inhibitor (CDKI) family. p27 expression is regulated by cell contact inhibition and by specific growth factors, such as transforming growth factor (TGF)-beta. Since the cloning of the p27 gene in 1994, a host of other functions have been associated with this cell cycle protein. In addition to its role as a CDKI, p27 is a putative tumor suppressor gene, regulator of drug resistance in solid tumors, and promoter of apoptosis; acts as a safeguard against inflammatory injury; and has a role in cell differentiation. The level of p27 protein expression decreases during tumor development and progression in some epithelial, lymphoid, and endocrine tissues. This decrease occurs mainly at the post-translational level with protein degradation by the ubiquitin-proteasome pathway. A large number of studies have characterized p27 as an independent prognostic factor in various human cancers, including breast, colon, and prostate adenocarcinomas. Here we review the role of p27 in the regulation of the cell cycle and other cell functions and as a diagnostic and prognostic marker in human neoplasms. We also review studies indicating the increasingly important roles of p27, other CDKIs, and cyclins in endocrine cell hyperplasia and tumor development.  (+info)

(7/40131) Angiogenesis: a new theory for endometriosis.

Excessive endometrial angiogenesis is proposed as an important mechanism in the pathogenesis of endometriosis. Evidence is reviewed for the hypothesis that the endometrium of women with endometriosis has an increased capacity to proliferate, implant and grow in the peritoneal cavity. Data is summarized indicating that the endometrium of patients with endometriosis shows enhanced endothelial cell proliferation. Results are also reviewed indicating that the cell adhesion molecule integrin alphavbeta3 is expressed in more blood vessels in the endometrium of women with endometriosis when compared with normal women. Taken together, these results provide evidence for increased endometrial angiogenesis in women with endometriosis when compared with normal subjects. Endometriosis is one of the family of angiogenic diseases. Other angiogenic diseases include solid tumours, rheumatoid arthritis, psoriasis and diabetic retanopathy. Excessive endometrial angiogenesis suggests novel new medical treatments for endometriosis aimed at the inhibition of angiogenesis.  (+info)

(8/40131) Osteopenia in the patient with cancer.

Osteopenia is defined as a reduction in bone mass. It is commonly known to occur in elderly people or women who are postmenopausal due to hormonal imbalances. This condition, however, can result because of many other factors, such as poor nutrition, prolonged pharmacological intervention, disease, and decreased mobility. Because patients with cancer experience many of these factors, they are often predisposed to osteopenia. Currently, patients with cancer are living longer and leading more fulfilling lives after treatment. Therefore, it is imperative that therapists who are responsible for these patients understand the risk factors for osteopenia and their relevance to a patient with cancer.  (+info)


What is the connection between malignant neoplasms and crabs?


The more common term for malignant neoplasms, cancer, is Latin for crab, and the word "carcinogen," meaning a cancer-causing agent, comes from the Greek word for crab, "karkinos."  What is the connection between these two seemingly unrelated things?
----------

Cancer, both the disease and the astronomical constellation, derive from the Latin cancer or cancrum, meaning crab. The astrological sign, of course, is said to resemble a crab and the disease was so named by the ancient Greek physician Galen (129-200 A.D.) who noted the similarity between a certain type of tumor with a crab as well—the swollen veins around the tumor resembling the legs of a crab. 

Old English adopted cancer directly from Latin and used it for a variety of spreading sores and ulcers. This early sense survives in the modern word canker. From c.1000 in a manuscript called Læce Boc (Leech Book), collected in Oswald Cockayne’s Leechdoms, Wortcunning, and Starcraft of Early England, Vol. II, 1865: 

Gemeng wið þam dustum, clæm on ðone cancer.
(Mix with the dust, smear on the cancer.)

And from Wyclif’s 2 Timothy, 1382: 

The word of hem crepith as a kankir

The word was being applied specifically to the disease we today call cancer by the beginning of the 17th century. From Philemon Holland’s translation of Pliny’s Historie of the World: 

Cancer is a swelling or sore comming of melancholy bloud, about which the veins appeare of a blacke or swert colour, spread in manner of a Creifish clees.

The astronomical sense of cancer is from the Latin name for the constellation of the crab. The name was known to the Anglo-Saxons, but only as a Latin name and was not assimilated into English until the Middle English period. It appears in Ælfric’s De Temporibus Anni, written c.993, in a list of the constellations of the Zodiac: 

Feorða • Cancer • þæt is Crabba
(Fourth, Cancer, that is the crab.)

The Anglicized name appears c.1391 in Chaucer’s Treatise on the Astrolabe: 

In this heved of cancer is the grettist declinacioun northward of the sonne...this signe of cancre is clepid the tropik of Somer.
(At this first point (head) of cancer is the greatest declination northward of the sun…this sign of cancer is named the tropic of summer.)

(Source: Oxford English Dictionary, 2nd Edition)


What is the basis of differing actions of antineoplastic agents on different tissue/neoplasms?


What is the basis for differing tissue- and neoplasm-specificites of antieoplastic chemotherapeutic agents? This doubt arose because considering what the pharmacokinetics of these drugs are it remains to be answered as to why a certain agent would act only in a particular tissue or neoplasm when the mechanisms they employ are so similar, e.g., various alkylating agents in spite having same action act of different tumors with differing degrees of effectiveness. Hope someone answers the question specifically. Useful links to free-text articles would also be highly appreciated. Bye. TC.
----------

If you have thoughts on this subject, you ought to have the initiative to research it yourself.


What are the harmful effects from small benign neoplasms arising from endocrine organs on the patient?


Give positive answers...
----------

Get to know them better. This is not a task only to be accomplished through dating. The more you get to know him or her, the more you can tell if you like them as a friend or something else. Just talk and do fun activities with the person. 
Stop and consider why you like the person. There are many physically attractive and smart people out there. But if you see something beyond that really catches your attention, you've marked this person as unique and probably like them. Why else would they stand out from so many? 
Consider how many times you think about the person. If you find yourself thinking about this person several times a day, and they are happy thoughts that possibly make your heart beat faster, then you probably like them. 
Think how often you laugh at their jokes etc. When you like someone, you will find yourself laughing at things even if they aren't that funny. This is a natural attempt to make them feel appreciated. 
If the one conversation between you and the person is stuck in you head and you cant stop telling people about it. this means it was important to you, and you probably like the person. 
Consider how much you try to be near them. If you've planned your walking speed to catch a glimpse of them as many times of the day as possible, there is a good reason for that. 
Think about how you feel if you touch him or her, by accident or on purpose. If you're still thinking about brushing shoulders several hours ago in school, then that is a special thought and you probably like them. 
If you feel you're ready for a relationship, and are confident enough for a positive response, then just go ahead and ask them out. If you're unsure of their feelings for you, there are several wikihows on how to tell if someone likes you.


term used to describe benign neoplasms made up of neurons and nerve fibers is a?


need some help with my h.w.
thanks!
----------

Neuroma

In the foot, check out this site...
http://www.footphysicians.com/footankleinfo/mortons-neuroma.htm


When can a tumor be non-cellular or non-neoplastic? And how can some neoplasms be cell free?


So basically, I've got a bio midterm tomorrow, and so in the process of studying, I realized I completely don't get that! Even my bio friends are like, what....? So if ANYONE can help us out here, that would be fantastic! Thanks!
----------

The word tumor is defined (in Answers.com) as "An abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function; a neoplasm." So your teacher is playing with semantics here.

The only way a "mass" could be non-cellular would be if it were cystic - - a contained area of fluid.  We see this with some ovarian tumors which may be benign or malignant.  The benign ones are ovarian serous cystadenomas or mucinous cystadenomas which can be quite large tumor masses.  These do contain cells however in the membranous sacs surrounding the fluid
http://www.mypacs.net/cases/MUCINOUS-CYSTADENOMA-OVARY-857115.html


What do you call a benign neoplasm arising from adipose tissue?


What do you call a benign neoplasm arising from adipose tissue?
----------

A fatty lipoma?


is thyroidectomy the ONLY way to determine if a papillary lesion / follicular neoplasm is benign or malignant?


My wife recently underwent FNAB for the thyroid gland and the findings were: 
1. PAPILLARY LESION 
2. FOLLICULAR NEOPLASM. 
Suggest thyroidectomy for a definitive diagnosis.
Microscopic Description:
Smears disclose a fairly cellular aspirate composed of cohesive clusters of follicular cells, in attempt to form acini and short papillary fronds. The cells show vesicular nuclei, with focal areas of pleomorphism. The background is hemorrhagic containing thin colloid materials and few mixed leukocytes.

I really would like to know if the it is benign or malignant but is there any other way besides invasive surgery? Thanks a lot in advance for all the answers and help.
----------

If FNAB demonstrate follicular neoplasm , we must perform thyroid lobectomy for determining if it's malignant or not , and regarding to this , we will design the further definite and main operation .
 
There is no way other than this yet .

In some situations , we can perform total thyroidectomy as a plan to determine the permanent pathology at first ( there is several indications : old patients , mass more than 4 cm , ... ) .

But about Papillary neoplasm it's somewhat different : we can plan for a definite operation , also with a FNAB .


How do you treat superior orbital fissure syndrome when the etiology is a neoplasm?


It's for school and I can't find the answer anywhere!
----------

Superior orbital fissure syndrome consists of retro-orbital pain, paralysis of extra ocular muscles, impairment of first trigeminal branches and frequent involvement of the optic nerve.
One must treat the neoplasm. That depends on its type. A glioblastoma would be treated differently from a lymphoma for example.